
## Piotr Ponikowski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4019717/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2016, 37, 2129-2200.	1.0	13,008
2	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2018, 39, 119-177.	1.0	7,100
3	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 2016, 37, 2893-2962.	1.0	5,689
4	2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal, 2013, 34, 2159-2219.	1.0	5,681
5	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	1.0	5,558
6	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2016, 18, 891-975.	2.9	5,272
7	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2012, 33, 1787-1847.	1.0	5,233
8	2017 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal, 2017, 38, 2739-2791.	1.0	5,142
9	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal, 2016, 37, 67-119.	1.0	5,074
10	2007 Guidelines for the Management of Arterial Hypertension. Journal of Hypertension, 2007, 25, 1105-1187.	0.3	4,778
11	Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal, 2010, 31, 2369-2429.	1.0	4,635
12	2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2019, 40, 87-165.	1.0	4,537
13	2013 ESH/ESC Guidelines for the management of arterial hypertension. Journal of Hypertension, 2013, 31, 1281-1357.	0.3	4,251
14	2014 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2014, 35, 2541-2619.	1.0	4,141
15	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2019, 381, 1995-2008.	13.9	4,108
16	2013 ESC guidelines on the management of stable coronary artery disease. European Heart Journal, 2013, 34, 2949-3003.	1.0	3,915
17	2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. European Heart Journal, 2014, 35, 2873-2926.	1.0	3,549
18	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 2016, 18, 1609-1678.	0.7	3,523

#	Article	IF	CITATIONS
19	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 2014, 35, 2733-2779.	1.0	3,469
20	Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. New England Journal of Medicine, 2015, 372, 2387-2397.	13.9	3,337
21	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. European Heart Journal, 2012, 33, 2719-2747.	1.0	3,144
22	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine, 2020, 383, 1413-1424.	13.9	2,821
23	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal,	1.0	2,656
24	2008, 29, 2008 2442. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal, 2014, 35, 3033-3080.	1.0	2,591
25	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Europace, 2012, 14, 1385-1413.	0.7	2,319
26	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Journal of Heart Failure, 2012, 14, 803-869.	2.9	2,307
27	2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Heart Journal, 2018, 39, 763-816.	1.0	2,305
28	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal, 2013, 34, 2281-2329.	1.0	2,176
29	2014 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2014, 46, 517-592.	0.6	2,164
30	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 2021, 385, 1451-1461.	13.9	2,143
31	Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet, The, 2010, 376, 875-885.	6.3	2,119
32	A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. New England Journal of Medicine, 2009, 361, 2019-2032.	13.9	2,110
33	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Heart Journal, 2016, 37, 2768-2801.	1.0	1,996
34	Cachexia: A new definition. Clinical Nutrition, 2008, 27, 793-799.	2.3	1,906
35	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008‡. European Journal of Heart Failure, 2008, 10, 933-989.	2.9	1,893
36	2015 ESC Guidelines for the diagnosis and management of pericardial diseases. European Heart Journal, 2015, 36, 2921-2964.	1.0	1,768

#	Article	IF	CITATIONS
37	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2013, 34, 3035-3087.	1.0	1,758
38	Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. New England Journal of Medicine, 2012, 367, 2089-2099.	13.9	1,754
39	Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. New England Journal of Medicine, 2012, 366, 9-19.	13.9	1,681
40	Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. New England Journal of Medicine, 2008, 359, 2456-2467.	13.9	1,663
41	Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. New England Journal of Medicine, 2009, 361, 2436-2448.	13.9	1,633
42	2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 2006, 28, 1462-1536.	1.0	1,617
43	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. New England Journal of Medicine, 2015, 372, 1791-1800.	13.9	1,585
44	Strategies for Multivessel Revascularization in Patients with Diabetes. New England Journal of Medicine, 2012, 367, 2375-2384.	13.9	1,573
45	2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. European Heart Journal, 2018, 39, 3165-3241.	1.0	1,396
46	Guidelines for the management of atrial fibrillation. Europace, 2010, 12, 1360-1420.	0.7	1,360
47	2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management. European Heart Journal, 2014, 35, 2383-2431.	1.0	1,253
48	Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet, The, 2009, 373, 2125-2135.	6.3	1,243
49	Wasting as independent risk factor for mortality in chronic heart failure. Lancet, The, 1997, 349, 1050-1053.	6.3	1,209
50	Dabigatran versus Warfarin in Patients with Mechanical Heart Valves. New England Journal of Medicine, 2013, 369, 1206-1214.	13.9	1,201
51	2018 ESC Guidelines for the diagnosis and management of syncope. European Heart Journal, 2018, 39, 1883-1948.	1.0	1,200
52	Effect of Nesiritide in Patients with Acute Decompensated Heart Failure. New England Journal of Medicine, 2011, 365, 32-43.	13.9	1,133
53	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. New England Journal of Medicine, 2021, 384, 117-128.	13.9	1,080
54	EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. European Heart Journal, 2006, 27, 2725-2736.	1.0	1,063

#	Article	IF	CITATIONS
55	The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet, The, 2012, 380, 1387-1395.	6.3	990
56	How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2019, 40, 3297-3317.	1.0	944
57	Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2008, 372, 807-816.	6.3	934
58	Heart failure: preventing disease and death worldwide. ESC Heart Failure, 2014, 1, 4-25.	1.4	921
59	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Journal of Heart Failure, 2017, 19, 9-42.	2.9	920
60	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace, 2013, 15, 1070-1118.	0.7	908
61	Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. European Heart Journal, 2015, 36, 657-668.	1.0	902
62	Increased Mortality after Dronedarone Therapy for Severe Heart Failure. New England Journal of Medicine, 2008, 358, 2678-2687.	13.9	901
63	Vorapaxar in the Secondary Prevention of Atherothrombotic Events. New England Journal of Medicine, 2012, 366, 1404-1413.	13.9	841
64	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	2.9	820
65	Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet, The, 2013, 381, 29-39.	6.3	810
66	Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. European Heart Journal, 2010, 31, 703-711.	1.0	797
67	Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects. New England Journal of Medicine, 2010, 363, 905-917.	13.9	791
68	Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. New England Journal of Medicine, 2012, 367, 1297-1309.	13.9	765
69	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2016, 50, e1-e88.	0.6	754
70	Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2020, 382, 1883-1893.	13.9	753
71	Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes. New England Journal of Medicine, 2011, 364, 907-917.	13.9	741
72	Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. European Heart Journal, 2009, 30, 2769-2812.	1.0	735

#	Article	IF	CITATIONS
73	Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. New England Journal of Medicine, 2012, 366, 20-33.	13.9	701
74	Cardiac-Resynchronization Therapy in Heart Failure with a Narrow QRS Complex. New England Journal of Medicine, 2013, 369, 1395-1405.	13.9	688
75	2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology, 2016, 23, NP1-NP96.	0.8	683
76	Hormonal Changes and Catabolic/Anabolic Imbalance in Chronic Heart Failure and Their Importance for Cardiac Cachexia. Circulation, 1997, 96, 526-534.	1.6	671
77	EUR <i>Observational</i> Research Programme: regional differences and 1â€year followâ€up results of the Heart Failure Pilot Survey (ESCâ€HF Pilot). European Journal of Heart Failure, 2013, 15, 808-817.	2.9	645
78	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. European Journal of Heart Failure, 2021, 23, 352-380.	2.9	630
79	Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet, The, 2009, 374, 29-38.	6.3	611
80	Defibrillator Implantation Early after Myocardial Infarction. New England Journal of Medicine, 2009, 361, 1427-1436.	13.9	605
81	Facilitated PCI in Patients with ST-Elevation Myocardial Infarction. New England Journal of Medicine, 2008, 358, 2205-2217.	13.9	596
82	Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. European Journal of Heart Failure, 2010, 12, 423-433.	2.9	593
83	Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. European Journal of Heart Failure, 2011, 13, 347-357.	2.9	580
84	Nutritional Recommendations for the Management of Sarcopenia. Journal of the American Medical Directors Association, 2010, 11, 391-396.	1.2	548
85	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2013, 15, 1173-1184.	2.9	533
86	Uric Acid and Survival in Chronic Heart Failure. Circulation, 2003, 107, 1991-1997.	1.6	532
87	Iron deficiency in chronic heart failure: An international pooled analysis. American Heart Journal, 2013, 165, 575-582.e3.	1.2	532
88	lron deficiency: an ominous sign in patients with systolic chronic heart failure. European Heart Journal, 2010, 31, 1872-1880.	1.0	515
89	Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm. New England Journal of Medicine, 2012, 366, 1859-1869.	13.9	511
90	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. New England Journal of Medicine, 2017, 376, 1527-1539.	13.9	510

#	Article	IF	CITATIONS
91	2017 ESC/EACTS Guidelines for the management of valvular heart disease. European Journal of Cardio-thoracic Surgery, 2017, 52, 616-664.	0.6	510
92	Clinical Correlates and Prognostic Significance of the Ventilatory Response to Exercise in Chronic Heart Failure. Journal of the American College of Cardiology, 1997, 29, 1585-1590.	1.2	505
93	Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 1169-1186.	2.9	490
94	Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and Nonanemic Patients With Symptomatic Chronic Heart Failure and Iron Deficiency. Journal of the American College of Cardiology, 2008, 51, 103-112.	1.2	488
95	Rolofylline, an Adenosine A <sub>1</sub> â^'Receptor Antagonist, in Acute Heart Failure. New England Journal of Medicine, 2010, 363, 1419-1428.	13.9	473
96	Mid-Region Pro-Hormone Markers for Diagnosis and Prognosis in Acute Dyspnea. Journal of the American College of Cardiology, 2010, 55, 2062-2076.	1.2	467
97	Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure. New England Journal of Medicine, 2013, 368, 1210-1219.	13.9	462
98	Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes. New England Journal of Medicine, 2009, 360, 2176-2190.	13.9	459
99	Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE/VCO2slope and peak VO2. European Heart Journal, 2000, 21, 154-161.	1.0	452
100	Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2009, 11, 433-443.	2.9	449
101	Depressed Heart Rate Variability as an Independent Predictor of Death in Chronic Congestive Heart Failure Secondary to Ischemic or Idiopathic Dilated Cardiomyopathy. American Journal of Cardiology, 1997, 79, 1645-1650.	0.7	436
102	2010 Focused Update of ESC Guidelines on device therapy in heart failure: An update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. European Heart Journal, 2010, 31, 2677-2687.	1.0	427
103	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet, The, 2020, 396, 1895-1904.	6.3	425
104	Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. European Heart Journal, 2013, 34, 2453-2463.	1.0	419
105	2018 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2019, 55, 4-90.	0.6	402
106	Prognostic Utility of Growth Differentiation Factor-15 in Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2007, 50, 1054-1060.	1.2	397
107	Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program. Journal of the American College of Cardiology, 2013, 61, 196-206.	1.2	397
108	Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet, The, 2009, 373, 1429-1439.	6.3	387

#	Article	IF	CITATIONS
109	Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors. European Heart Journal, 2020, 41, 1810-1817.	1.0	381
110	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. New England Journal of Medicine, 2021, 384, 105-116.	13.9	381
111	Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet, The, 2016, 387, 1178-1186.	6.3	373
112	Universal Definition and Classification of Heart Failure. Journal of Cardiac Failure, 2021, 27, 387-413.	0.7	362
113	2013 ESH/ESC Guidelines for the management of arterial hypertension. Blood Pressure, 2013, 22, 193-278.	0.7	355
114	Skeletal Muscle Function and Its Relation to Exercise Tolerance in Chronic Heart Failure. Journal of the American College of Cardiology, 1997, 30, 1758-1764.	1.2	352
115	Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2011, 13, 1-10.	2.9	350
116	Enhanced Ventilatory Response to Exercise in Patients With Chronic Heart Failure and Preserved Exercise Tolerance. Circulation, 2001, 103, 967-972.	1.6	348
117	Anabolic Deficiency in Men With Chronic Heart Failure. Circulation, 2006, 114, 1829-1837.	1.6	346
118	The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nature Medicine, 2022, 28, 568-574.	15.2	341
119	EUR <i>Observational</i> Research Programme: The Heart Failure Pilot Survey (ESCâ€HF Pilot). European Journal of Heart Failure, 2010, 12, 1076-1084.	2.9	340
120	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA - Journal of the American Medical Association, 2020, 323, 1353.	3.8	340
121	Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2007, 9, 684-694.	2.9	335
122	Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. European Heart Journal, 1999, 20, 683-693.	1.0	321
123	Effects of ferric carboxymaltose on hospitalisations and mortality rates in ironâ€deficient heart failure patients: an individual patient data metaâ€analysis. European Journal of Heart Failure, 2018, 20, 125-133.	2.9	317
124	Recommendations on preâ€hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. European Journal of Heart Failure, 2015, 17, 544-558.	2.9	315
125	Effect on Survival and Hospitalization of Initiating Treatment for Chronic Heart Failure With Bisoprolol Followed by Enalapril, as Compared With the Opposite Sequence. Circulation, 2005, 112, 2426-2435.	1.6	305
126	Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. European Heart Journal, 2013, 34, 816-829.	1.0	304

#	Article	IF	CITATIONS
127	Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. European Heart Journal, 2017, 38, 1883-1890.	1.0	299
128	2010 Focused Update of ESC Guidelines on device therapy in heart failure. Europace, 2010, 12, 1526-1536.	0.7	297
129	2007 ESHâ€ESC Guidelines for the management of arterial hypertension. Blood Pressure, 2007, 16, 135-232.	0.7	292
130	Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. Circulation, 2017, 136, 1374-1383.	1.6	289
131	Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2015, 314, 2251.	3.8	288
132	Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. European Heart Journal, 2009, 30, 540-548.	1.0	286
133	Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. European Heart Journal, 2017, 38, 1119-1127.	1.0	285
134	Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2009, 11, 119-129.	2.9	281
135	Diuretic response in acute heart failure: clinical characteristics and prognostic significance. European Heart Journal, 2014, 35, 1284-1293.	1.0	276
136	A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. European Heart Journal, 2016, 37, 2105-2114.	1.0	274
137	Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome. JAMA - Journal of the American Medical Association, 2014, 311, 252.	3.8	270
138	Effects of intravenous iron therapy in ironâ€deficient patients with systolic heart failure: a metaâ€analysis of randomized controlled trials. European Journal of Heart Failure, 2016, 18, 786-795.	2.9	270
139	Large Animal Models of Heart Failure. Circulation: Heart Failure, 2009, 2, 262-271.	1.6	267
140	Peripheral Chemoreceptor Hypersensitivity. Circulation, 2001, 104, 544-549.	1.6	264
141	A trial to evaluate the effect of the sodium–glucose coâ€transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPAâ€HF). European Journal of Heart Failure, 2019, 21, 665-675.	2.9	264
142	Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. European Journal of Anaesthesiology, 2010, 27, 92-137.	0.7	263
143	Adherence of heart failure patients to exercise: barriers and possible solutions. European Journal of Heart Failure, 2012, 14, 451-458.	2.9	263
144	Distribution and Risk Profile of Paroxysmal, Persistent, and Permanent Atrial Fibrillation in Routine Clinical Practice. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 632-639.	2.1	259

#	Article	IF	CITATIONS
145	Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. New England Journal of Medicine, 2017, 376, 1956-1964.	13.9	257
146	Impaired Insulin Sensitivity as an Independent Risk Factor for Mortality in Patients With Stable Chronic Heart Failure. Journal of the American College of Cardiology, 2005, 46, 1019-1026.	1.2	249
147	Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. European Heart Journal, 2008, 30, 478-486.	1.0	247
148	Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction. Circulation, 2020, 141, 90-99.	1.6	244
149	Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet, The, 2016, 388, 2895-2903.	6.3	229
150	Iron Deficiency Predicts Impaired Exercise Capacity in Patients With Systolic Chronic Heart Failure. Journal of Cardiac Failure, 2011, 17, 899-906.	0.7	227
151	Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. European Journal of Heart Failure, 2019, 21, 827-843.	2.9	223
152	Improving care for patients with acute heart failure: before, during and after hospitalization. ESC Heart Failure, 2014, 1, 110-145.	1.4	222
153	Augmented Peripheral Chemosensitivity as a Potential Input to Baroreflex Impairment and Autonomic Imbalance in Chronic Heart Failure. Circulation, 1997, 96, 2586-2594.	1.6	221
154	Iron deficiency and cardiovascular disease. Nature Reviews Cardiology, 2015, 12, 659-669.	6.1	220
155	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status. Circulation, 2021, 143, 337-349.	1.6	217
156	Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. European Journal of Heart Failure, 2010, 12, 239-248.	2.9	214
157	Iron status in patients with chronic heart failure. European Heart Journal, 2013, 34, 827-834.	1.0	212
158	A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clinical Science, 2007, 113, 205-212.	1.8	210
159	Muscle Ergoreceptor Overactivity Reflects Deterioration in Clinical Status and Cardiorespiratory Reflex Control in Chronic Heart Failure. Circulation, 2001, 104, 2324-2330.	1.6	208
160	Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus. JAMA - Journal of the American Medical Association, 2014, 311, 1515.	3.8	206
161	Effect of Darbepoetin Alfa on Exercise Tolerance in Anemic Patients With Symptomatic Chronic Heart Failure. Journal of the American College of Cardiology, 2007, 49, 753-762.	1.2	203
162	Identifying Pathophysiological Mechanisms in Heart Failure WithÂReduced Versus Preserved EjectionÂFraction. Journal of the American College of Cardiology, 2018, 72, 1081-1090.	1.2	199

#	Article	IF	CITATIONS
163	Dronedarone for the control of ventricular rate in permanent atrial fibrillation: The Efficacy and safety of dRonedArone for The cOntrol of ventricular rate during atrial fibrillation (ERATO) study. American Heart Journal, 2008, 156, 527.e1-527.e9.	1.2	197
164	Oscillatory Breathing Patterns During Wakefulness in Patients With Chronic Heart Failure. Circulation, 1999, 100, 2418-2424.	1.6	196
165	Iron Deficiency in Heart Failure. JACC: Heart Failure, 2019, 7, 36-46.	1.9	195
166	The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction. European Heart Journal, 2015, 36, 1974-1982.	1.0	193
167	Physicians' adherence to guidelineâ€recommended medications in heart failure with reduced ejection fraction: data from the <scp>QUALIFY</scp> global survey. European Journal of Heart Failure, 2016, 18, 514-522.	2.9	193
168	How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2020, 22, 391-412.	2.9	193
169	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. Circulation, 2021, 143, 298-309.	1.6	193
170	Acute Treatment With Omecamtiv Mecarbil to Increase Contractility inÂAcuteÂHeart Failure. Journal of the American College of Cardiology, 2016, 67, 1444-1455.	1.2	191
171	Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrology Dialysis Transplantation, 2010, 25, 1406-1416.	0.4	188
172	Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. European Heart Journal, 2007, 28, 2208-2216.	1.0	184
173	Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. American Heart Journal, 2009, 158, 896-901.e3.	1.2	184
174	Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. European Journal of Heart Failure, 2017, 19, 627-634.	2.9	183
175	Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the <scp>QUALIFY</scp> international registry. European Journal of Heart Failure, 2017, 19, 1414-1423.	2.9	183
176	Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. European Journal of Heart Failure, 2013, 15, 1082-1094.	2.9	182
177	Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. European Heart Journal, 2014, 35, 2468-2476.	1.0	179
178	Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nature Reviews Cardiology, 2011, 8, 485-493.	6.1	175
179	Effects of Serelaxin in Patients with Acute Heart Failure. New England Journal of Medicine, 2019, 381, 716-726.	13.9	174
180	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary. Diabetes and Vascular Disease Research, 2014, 11, 133-173.	0.9	173

#	Article	IF	CITATIONS
181	The clinical significance of interleukinâ€6 in heart failure: results from the BIOSTATâ€CHF study. European Journal of Heart Failure, 2019, 21, 965-973.	2.9	172
182	Acute heart failure congestion and perfusion status–Âimpact of the clinical classification on inâ€hospital and longâ€term outcomes; insights from the ESCâ€EORPâ€HFA Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2019, 21, 1338-1352.	2.9	170
183	Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2020, 324, 1512.	3.8	170
184	Increased 90-Day Mortality in Patients With Acute Heart Failure With Elevated Copeptin. Circulation: Heart Failure, 2011, 4, 613-620.	1.6	165
185	Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy ( <scp>PPCM</scp> ). European Journal of Heart Failure, 2017, 19, 1131-1141.	2.9	163
186	Signature of circulating <scp>microRNAs</scp> in patients with acute heart failure. European Journal of Heart Failure, 2016, 18, 414-423.	2.9	162
187	The PROTECT Pilot Study: A Randomized, Placebo-Controlled, Dose-Finding Study of the Adenosine A1 Receptor Antagonist Rolofylline in Patients With Acute Heart Failure and Renal Impairment. Journal of Cardiac Failure, 2008, 14, 631-640.	0.7	160
188	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the <scp>Heart Failure Association of the European Society of Cardiology</scp> . European Journal of Heart Failure, 2021, 23, 872-881.	2.9	160
189	Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet, The, 2008, 371, 228-236.	6.3	159
190	The Predictive Value of Short-Term Changes in Hemoglobin Concentration in Patients Presenting With Acute Decompensated Heart Failure. Journal of the American College of Cardiology, 2013, 61, 1973-1981.	1.2	159
191	The Dapagliflozin And Prevention of Adverseâ€outcomes in Heart Failure (DAPAâ€HF) trial: baseline characteristics. European Journal of Heart Failure, 2019, 21, 1402-1411.	2.9	159
192	Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. International Journal of Cardiology, 2018, 258, 185-191.	0.8	157
193	Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 3-15.	2.9	157
194	Evaluation of the effect of sodium–glucose coâ€ŧransporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPERORâ€Reduced trial. European Journal of Heart Failure, 2019, 21, 1270-1278.	2.9	155
195	Effect of ivabradine in patients with heart failure with preserved ejection fraction: the <scp>EDIFY</scp> randomized placeboâ€controlled trial. European Journal of Heart Failure, 2017, 19, 1495-1503.	2.9	154
196	2010 Focused Update of ESC Guidelines on device therapy in heart failure. European Journal of Heart Failure, 2010, 12, 1143-1153.	2.9	152
197	Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. European Heart Journal, 2020, 41, 2379-2392.	1.0	151
198	A systems <scp>BIOlogy</scp> Study to <scp>TAilored</scp> Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of <scp>BIOSTAT HF</scp> . European Journal of Heart Failure, 2016, 18, 716-726.	2.9	149

#	Article	IF	CITATIONS
199	Iron deficiency and health-related quality of life in chronic heart failure: Results from a multicenter European study. International Journal of Cardiology, 2014, 174, 268-275.	0.8	147
200	Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent. Journal of the American College of Cardiology, 2008, 51, 2276-2285.	1.2	145
201	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age. Circulation, 2020, 141, 100-111.	1.6	145
202	Heart Failure Association of the European Society ofÂCardiology position paper on frailty in patients with heart failure. European Journal of Heart Failure, 2019, 21, 1299-1305.	2.9	144
203	Maintenance of serum potassium with sodium zirconium cyclosilicate ( <scp>ZS</scp> â€9) in heart failure patients: results from a phase 3 randomized, doubleâ€blind, placeboâ€controlled trial. European Journal of Heart Failure, 2015, 17, 1050-1056.	2.9	143
204	Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. Lancet, The, 2016, 388, 974-982.	6.3	142
205	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the EfficacyÂand Safety of the Oral Soluble Guanylate Cyclase Stimulator. JACC: Heart Failure, 2018, 6, 96-104.	1.9	141
206	Effects of Vildagliptin on Ventricular Function in Patients With Type 2 DiabetesÂMellitus and Heart Failure. JACC: Heart Failure, 2018, 6, 8-17.	1.9	140
207	Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. International Journal of Cardiology, 2018, 271, 132-139.	0.8	140
208	Comparison of Midregional Pro-Atrial Natriuretic Peptide With N-Terminal Pro-B-Type Natriuretic Peptide in Predicting Survival in Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2007, 50, 1973-1980.	1.2	139
209	The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. European Heart Journal, 2013, 34, 30-38.	1.0	139
210	The potential role and rationale for treatment of heart failure with sodium–glucose coâ€ŧransporter 2 inhibitors. European Journal of Heart Failure, 2017, 19, 1390-1400.	2.9	139
211	Effects of Dihydrocodeine on Chemosensitivity and Exercise Tolerance in Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 1997, 29, 147-152.	1.2	136
212	Reduced Peripheral Skeletal Muscle Mass and Abnormal Reflex Physiology in Chronic Heart Failure. Circulation, 2006, 114, 126-134.	1.6	135
213	Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II. European Journal of Heart Failure, 2008, 10, 140-148.	2.9	134
214	Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes. Circulation: Heart Failure, 2010, 3, 314-325.	1.6	134
215	Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome—an analysis from <scp>RELAXâ€AHF</scp> . European Journal of Heart Failure, 2014, 16, 1230-1240.	2.9	134
216	Accuracy and Efficiency of Coupled-Cluster Theory Using Density Fitting/Cholesky Decomposition, Frozen Natural Orbitals, and a <i>t</i> <sub>1</sub> -Transformed Hamiltonian. Journal of Chemical Theory and Computation, 2013, 9, 2687-2696.	2.3	131

#	Article	IF	CITATIONS
217	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucoseâ€lowering drugs in patients with heart failure. European Journal of Heart Failure, 2020, 22, 196-213.	2.9	131
218	Home telemonitoring in heart failure patients: the HHH study (Home or Hospital in Heart Failure). European Journal of Heart Failure, 2009, 11, 312-318.	2.9	130
219	Intravenous ferric carboxymaltose in ironâ€deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIRâ€HF trial. European Journal of Heart Failure, 2013, 15, 1267-1276.	2.9	130
220	ESPEN Guidelines on Enteral Nutrition: Cardiology and Pulmonology. Clinical Nutrition, 2006, 25, 311-318.	2.3	128
221	Midregion Prohormone Adrenomedullin and Prognosis in Patients Presenting With Acute Dyspnea. Journal of the American College of Cardiology, 2011, 58, 1057-1067.	1.2	128
222	A neural link to explain the "muscle hypothesis―of exercise intolerance in chronic heart failure. American Heart Journal, 1999, 137, 1050-1056.	1.2	126
223	Effect of anemia on exercise tolerance in chronic heart failure in men. American Journal of Cardiology, 2003, 91, 888-891.	0.7	125
224	Effects of the Adenosine A1 Receptor Antagonist Rolofylline on Renal Function in Patients With Acute Heart Failure and Renal Dysfunction. Journal of the American College of Cardiology, 2011, 57, 1899-1907.	1.2	125
225	Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. European Heart Journal, 2021, 42, 3727-3738.	1.0	125
226	Relation of heart rate and blood pressure turbulence following premature ventricular complexes to baroreflex sensitivity in chronic congestive heart failure. American Journal of Cardiology, 2001, 87, 737-742.	0.7	123
227	Treatments targeting inotropy. European Heart Journal, 2019, 40, 3626-3644.	1.0	123
228	Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial. European Journal of Heart Failure, 2012, 14, 278-286.	2.9	122
229	Mechanisms and Clinical Consequences ofÂUntreated Central Sleep Apnea in HeartÂFailure. Journal of the American College of Cardiology, 2015, 65, 72-84.	1.2	120
230	Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2021, 6, 499.	3.0	120
231	Rationale and design of the <scp>SOluble</scp> guanylate Cyclase <scp>stimulatoR</scp> in <scp>heArT failurE</scp> Studies ( <scp>SOCRATES</scp> ). European Journal of Heart Failure, 2014, 16, 1026-1038.	2.9	119
232	Definition and classification of Cardio-Renal Syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrology Dialysis Transplantation, 2010, 25, 1416-1420.	0.4	118
233	Transvenous phrenic nerve stimulation for the treatment of central sleep apnoea in heart failure. European Heart Journal, 2012, 33, 889-894.	1.0	118
234	Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Failure Reviews, 2013, 18, 123-134.	1.7	118

#	Article	IF	CITATIONS
235	Midâ€regional proâ€adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. European Journal of Heart Failure, 2010, 12, 484-491.	2.9	117
236	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. European Heart Journal, 2021, 42, 700-710.	1.0	117
237	The PROTECT inâ€hospital risk model: 7â€day outcome in patients hospitalized with acute heart failure and renal dysfunction. European Journal of Heart Failure, 2012, 14, 605-612.	2.9	115
238	The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2017, 19, 1361-1378.	2.9	115
239	Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea. JACC: Heart Failure, 2015, 3, 360-369.	1.9	114
240	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 1203-1212.	1.0	114
241	One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	1.6	113
242	Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 180-188.	1.4	113
243	Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the <scp>RELAXâ€AHF</scp> study. European Journal of Heart Failure, 2015, 17, 1262-1270.	2.9	110
244	Autonomic imbalance and immune activation in chronic heart failure — Pathophysiological links. Cardiovascular Research, 2006, 70, 434-445.	1.8	109
245	Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry. Heart, 2012, 98, 195-201.	1.2	109
246	Predicting heart failure outcome from cardiac and comorbid conditions: The 3C-HF score. International Journal of Cardiology, 2013, 163, 206-211.	0.8	108
247	Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (REDâ€HF): a Phase III, anaemia correction, morbidity–mortality trial. European Journal of Heart Failure, 2009, 11, 795-801.	2.9	107
248	Atrial Fibrillation Impairs the Diagnostic Performance of Cardiac Natriuretic Peptides in Dyspneic Patients. JACC: Heart Failure, 2013, 1, 192-199.	1.9	107
249	Predictors of Postdischarge Outcomes From Information Acquired Shortly After Admission for Acute Heart Failure. Circulation: Heart Failure, 2014, 7, 76-87.	1.6	107
250	CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients—who is doing what to whom and how?. European Journal of Heart Failure, 2018, 20, 1039-1051.	2.9	107
251	Cardiorenal Syndromes: An Executive Summary from the Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). Contributions To Nephrology, 2010, 165, 54-67.	1.1	106
252	Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. Circulation, 2022, 145, 184-193.	1.6	106

#	Article	IF	CITATIONS
253	Rationale and design of Ferinject® Assessment in patients with IRon deficiency and chronic Heart Failure (FAIRâ€HF) study: a randomized, placeboâ€controlled study of intravenous iron supplementation in patients with and without anaemia. European Journal of Heart Failure, 2009, 11, 1084-1091.	2.9	105
254	Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. European Journal of Heart Failure, 2012, 14, 1056-1066.	2.9	105
255	Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine – short version. European Heart lournal. 2015. 36. 1958-1966.	1.0	105
256	A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. European Heart Journal, 2014, 35, 431-441.	1.0	104
257	The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the Studies Investigating Co-morbidities Aggravating Heart Failure. International Journal of Cardiology, 2016, 205, 6-12.	0.8	104
258	Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAXâ€AHFâ€2 study. European Journal of Heart Failure, 2017, 19, 800-809.	2.9	104
259	The influence of iron deficiency on the functioning of skeletal muscles: experimental evidence and clinical implications. European Journal of Heart Failure, 2016, 18, 762-773.	2.9	102
260	Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). European Heart Journal, 2017, 38, 2364-2373.	1.0	102
261	Effect of Estrogen Replacement Therapy on Heart Rate Variability and Heart Rate in HealthyPostmenopausal Women. American Journal of Cardiology, 1997, 80, 815-817.	0.7	101
262	Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. European Heart Journal, 2020, 41, 3787-3797.	1.0	101
263	Sodium–glucose coâ€transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1495-1503.	2.9	100
264	Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Preâ€RELAXâ€AHF. European Journal of Heart Failure, 2011, 13, 961-967.	2.9	99
265	<pre><scp>EURObservational</scp> Research Programme: a worldwide registry on peripartum cardiomyopathy (<scp>PPCM</scp>) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on <scp>PPCM</scp>. European Journal of Heart Failure. 2014. 16. 583-591.</pre>	2.9	99
266	Carotid body resection for sympathetic modulation in systolic heart failure: results from firstâ€inâ€man study. European Journal of Heart Failure, 2017, 19, 391-400.	2.9	97
267	Abnormal autonomic control of the cardiovascular system in syndrome X. American Journal of Cardiology, 1994, 73, 1174-1179.	0.7	95
268	Management of heart failure patients with <scp>COVID</scp> â€19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 941-956.	2.9	95
269	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPERORâ€Preserved trial. European Journal of Heart Failure, 2020, 22, 2383-2392.	2.9	93
270	The impact of intravenous ferric carboxymaltose on renal function: an analysis of the <scp>FAIRâ€HF</scp> study. European Journal of Heart Failure, 2015, 17, 329-339.	2.9	92

#	Article	IF	CITATIONS
271	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the <scp>Translational Research Committee</scp> of the <scp>Heart Failure Association</scp> ( <scp>HFA</scp> ) of the <scp>European Society of Cardiology</scp> ( <scp>ESC</scp> ). European Journal of Heart Failure, 2020, 22, 2272-2289.	2.9	92
272	Statin use and survival in patients with chronic heart failure $\hat{a} \in$ " results from two observational studies with 5200 patients. International Journal of Cardiology, 2006, 112, 234-242.	0.8	90
273	Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. European Heart Journal, 2014, 35, 1041-1050.	1.0	90
274	Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). European Heart Journal, 2020, 41, 3402-3418.	1.0	90
275	Circulating Estradiol and Mortality in Men With Systolic Chronic Heart Failure. JAMA - Journal of the American Medical Association, 2009, 301, 1892.	3.8	88
276	Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Preâ€RELAXâ€AHF study. European Journal of Heart Failure, 2010, 12, 1130-1139.	2.9	88
277	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. American Heart Journal, 2015, 169, 631-638.e7.	1.2	88
278	N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes. JACC: Heart Failure, 2020, 8, 931-939.	1.9	88
279	Reduction in Circulating Testosterone Relates to Exercise Capacity in Men With Chronic Heart Failure. Journal of Cardiac Failure, 2009, 15, 442-450.	0.7	87
280	Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan. JACC: Heart Failure, 2020, 8, 811-818.	1.9	87
281	Contribution of skeletal muscle â€~ergoreceptors' in the human leg to respiratory control in chronic heart failure. Journal of Physiology, 2000, 529, 863-870.	1.3	86
282	Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. European Heart Journal, 2007, 28, 821-828.	1.0	86
283	Growth differentiation factor 15 ( <scp>GDF</scp> â€45) in patients admitted for acute heart failure: results from the <scp>RELAXâ€AHF</scp> study. European Journal of Heart Failure, 2015, 17, 1133-1143.	2.9	86
284	Physicians' guideline adherence is associated with longâ€ŧerm heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. European Journal of Heart Failure, 2019, 21, 921-929.	2.9	86
285	Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. European Heart Journal, 2009, 30, 1331-1339.	1.0	85
286	Increased blood lactate is prevalent and identifies poor prognosis in patients with acute heart failure without overt peripheral hypoperfusion. European Journal of Heart Failure, 2018, 20, 1011-1018.	2.9	85
287	Waistâ€ŧoâ€hip ratio and mortality in heart failure. European Journal of Heart Failure, 2018, 20, 1269-1277.	2.9	85
288	Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. European Heart Journal, 2011, 32, 1519-1534.	1.0	84

#	Article	IF	CITATIONS
289	Patientâ€reported outcomes in the <scp>SOluble</scp> guanylate Cyclase <scp>stimulatoR</scp> in <scp>heArT failurE patientS</scp> with <scp>PRESERVED</scp> ejection fraction ( <scp>SOCRATESâ€PRESERVED</scp> ) study. European Journal of Heart Failure, 2017, 19, 782-791.	2.9	84
290	Carotid body removal for treatment of chronic systolic heart failure. International Journal of Cardiology, 2013, 168, 2506-2509.	0.8	83
291	Cardiopulmonary exercise testing in systolic heart failure in 2014: the evolving prognostic role. European Journal of Heart Failure, 2014, 16, 929-941.	2.9	83
292	Contemporary real life cardioversion of atrial fibrillation: Results from the multinational RHYTHM-AF study. International Journal of Cardiology, 2014, 172, 588-594.	0.8	83
293	Impact of Serial Troponin Release on Outcomes in Patients With Acute Heart Failure. Circulation: Heart Failure, 2011, 4, 724-732.	1.6	82
294	A multimarker multiâ€ŧime pointâ€based risk stratification strategy in acute heart failure: results from the <scp>RELAXâ€AHF</scp> trial. European Journal of Heart Failure, 2017, 19, 1001-1010.	2.9	81
295	Elevation in High-Sensitivity Troponin T in Heart Failure and Preserved Ejection Fraction and Influence of Treatment With the Angiotensin Receptor Neprilysin Inhibitor LCZ696. Circulation: Heart Failure, 2014, 7, 953-959.	1.6	80
296	Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	80
297	Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure. Gene Therapy, 2016, 23, 313-319.	2.3	79
298	Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from <scp>BIOSTATâ€CHF</scp> . European Journal of Heart Failure, 2017, 19, 1284-1293.	2.9	79
299	Biomarker Profiles of AcuteÂHeartÂFailureÂPatients With aÂMid-Range EjectionÂFraction. JACC: Heart Failure, 2017, 5, 507-517.	1.9	78
300	The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. European Heart Journal, 2021, 42, 1254-1269.	1.0	78
301	Design and Rationale of the PROTECT Study: A Placebo-controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function. Journal of Cardiac Failure, 2010, 16, 25-35.	0.7	76
302	Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Coâ€morbidities Aggravating Heart Failure (SICAâ€HF). Journal of Cachexia, Sarcopenia and Muscle, 2010, 1, 187-194.	2.9	75
303	Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. European Journal of Heart Failure, 2013, 15, 947-959.	2.9	75
304	Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists. JACC: Heart Failure, 2021, 9, 254-264.	1.9	75
305	Ursodeoxycholic Acid in Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2012, 59, 585-592.	1.2	74
306	Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Studyâ€Heart Failure (ARTSâ€HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. European Journal of Heart Failure, 2015, 17, 224-232.	2.9	74

#	Article	IF	CITATIONS
307	Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure. Heart, 2017, 103, 407-413.	1.2	74
308	Telerehabilitation in heart failure patients: The evidence and the pitfalls. International Journal of Cardiology, 2016, 220, 408-413.	0.8	73
309	Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF. Journal of the American College of Cardiology, 2021, 78, 97-108.	1.2	73
310	Rationale and design of ARTS: a randomized, doubleâ€blind study of BAY 94â€8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. European Journal of Heart Failure, 2012, 14, 668-675.	2.9	72
311	Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency. European Journal of Heart Failure, 2012, 14, 882-886.	2.9	71
312	Thromboâ€embolism and antithrombotic therapy for heart failure in sinus rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. European Journal of Heart Failure, 2012, 14, 681-695.	2.9	71
313	International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better shortâ€ŧerm outcomes in patients enrolled in Eastern Europe and Russia in the <scp>PROTECT</scp> trial. European Journal of Heart Failure, 2014, 16, 614-624.	2.9	71
314	Iron deficiency as energetic insult to skeletal muscle in chronic diseases. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 802-815.	2.9	71
315	Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 999-1005.	2.9	71
316	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. European Heart Journal, 2021, 42, 3011-3020.	1.0	71
317	Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the <scp>PROTECT</scp> study. European Journal of Heart Failure, 2016, 18, 830-839.	2.9	70
318	Prognostic value of changes over time in exercise capacity and echocardiographic measurements in patients with chronic heart failure. European Heart Journal, 2000, 21, 146-153.	1.0	69
319	Skeletal myopathy in patients with chronic heart failure: significance of anabolicâ€androgenic hormones. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 287-296.	2.9	69
320	<scp>ExtraHF</scp> survey: the first European survey on implementation of exercise training in heart failure patients. European Journal of Heart Failure, 2015, 17, 631-638.	2.9	69
321	Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. European Heart Journal, 2015, 36, 715-723.	1.0	69
322	Optimizing clinical use of biomarkers in highâ€risk acute heart failure patients. European Journal of Heart Failure, 2016, 18, 269-280.	2.9	69
323	Heart Failure Therapeutics on theÂBasisÂofÂaÂBiased Ligand of theÂAngiotensin-2 TypeÂ1ÂReceptor. JACC: Heart Failure, 2015, 3, 193-201.	1.9	68
324	Association with outcomes and response to treatment of trimethylamine Nâ€oxide in heart failure: results from BIOSTATâ€CHF. European Journal of Heart Failure, 2019, 21, 877-886.	2.9	68

#	Article	IF	CITATIONS
325	Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. International Journal of Cardiology, 2016, 203, 909-915.	0.8	67
326	What have we learned about heart failure with midâ€range ejection fraction one year after its introduction?. European Journal of Heart Failure, 2017, 19, 1569-1573.	2.9	67
327	Sodium–glucose coâ€ŧransporter 2 inhibitors as an early, firstâ€line therapy in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2022, 24, 431-441.	2.9	67
328	<scp>Heart Failure Association</scp> of the <scp>European Society of Cardiology</scp> update on sodium–glucose coâ€transporter 2 inhibitors in heart failure. European Journal of Heart Failure, 2020, 22, 1984-1986.	2.9	66
329	Chronic heart failure in the elderly: value of cardiopulmonary exercise testing in risk stratification. British Heart Journal, 2000, 83, 147-151.	2.2	65
330	Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure. International Journal of Cardiology, 2007, 115, 151-155.	0.8	65
331	Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm. Thrombosis and Haemostasis, 2012, 108, 1009-1022.	1.8	65
332	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with) Tj ETQq0 0 0 rgB	T /Qverloc	k 10 Tf 50 46
333	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 2109-2117.	1.0	65
334	Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. Circulation, 2022, 146, 279-288.	1.6	65
335	Shortâ€ŧerm Mortality Risk in Emergency Department Acute Heart Failure. Academic Emergency Medicine, 2011, 18, 947-958.	0.8	64
336	Phrenic nerve stimulation to treat patients with central sleep apnoea and heart failure. European Journal of Heart Failure, 2018, 20, 1746-1754.	2.9	64
337	The 12-week progressive quadriceps resistance training improves muscle strength, exercise capacity and quality of life in patients with stable chronic heart failure. International Journal of Cardiology, 2008, 130, 36-43.	0.8	63
338	Serial assessment of spot urine sodium predicts effectiveness of decongestion and outcome in patients with acute heart failure. European Journal of Heart Failure, 2019, 21, 624-633.	2.9	63
339	Detection and significance of a discrete very low frequency rhythm in RR interval variability in chronic congestive heart failure. American Journal of Cardiology, 1996, 77, 1320-1326.	0.7	61
340	Ventilatory response to exercise correlates with impaired heart rate variability in patients with chronic congestive heart failure. American Journal of Cardiology, 1998, 82, 338-344.	0.7	60
341	The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. Journal of the American College of Cardiology, 2000, 36, 523-528.	1.2	60
342	Design of the RELAXin in Acute Heart Failure Study. American Heart Journal, 2012, 163, 149-155.e1.	1.2	60

(

#	Article	IF	CITATIONS
343	Renal Function Trajectories and Clinical Outcomes in Acute Heart Failure. Circulation: Heart Failure, 2014, 7, 59-67.	1.6	60
344	Inâ€hospital worsening heart failure. European Journal of Heart Failure, 2015, 17, 1104-1113.	2.9	60
345	Sodium–glucose coâ€transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the <scp>EMPULSE</scp> trial. European Journal of Heart Failure, 2021, 23, 826-834.	2.9	60
346	Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60â€day outcomes in the PROTECT pilot study. European Journal of Heart Failure, 2010, 12, 499-507.	2.9	59
347	The additive burden of iron deficiency in the cardiorenal–anaemia axis: scope of a problem and its consequences. European Journal of Heart Failure, 2014, 16, 655-662.	2.9	59
348	Trimetazidine in cardiovascular medicine. International Journal of Cardiology, 2019, 293, 39-44.	0.8	59
349	Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion. Circulation: Heart Failure, 2018, 11, e004644.	1.6	58
350	Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the <scp>VICTORIA</scp> ( <scp>Vericiguat</scp> Global Study in) Tj ETQq0 0 (	) rg₿.₽/Ov	erlo <b>a</b> ak 10 Tf 5
351	Potassium and the use of renin–angiotensin–aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTATâ€CHF. European Journal of Heart Failure, 2018, 20, 923-930.	2.9	57
352	Effect of dapagliflozin on anaemia in <scp>DAPAâ€HF</scp> . European Journal of Heart Failure, 2021, 23, 617-628.	2.9	57
353	Contribution of peripheral chemoreceptors to ventilation and the effects of their suppression on exercise tolerance in chronic heart failure Heart, 1996, 76, 483-489.	1.2	56
354	Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. European Heart Journal, 2013, 34, 3128-3136.	1.0	56
355	Effect of Serelaxin on Mode of Death inÂAcute Heart Failure. Journal of the American College of Cardiology, 2014, 64, 1591-1598.	1.2	56
356	Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction. Annals of Internal Medicine, 2022, 175, 820-830.	2.0	56
357	Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. International Journal of Cardiology, 2018, 253, 84-90.	0.8	55
358	Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure. International Journal of Cardiology, 1998, 66, 1-10.	0.8	54
359	Bone mineral status and bone loss over time in men with chronic systolic heart failure and their clinical and hormonal determinants. European Journal of Heart Failure, 2009, 11, 28-38.	2.9	54
360	2013 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy. Revista Espanola De Cardiologia (English Ed ), 2014, 67, 58.	0.4	54

#	Article	IF	CITATIONS
361	Iron deficiency and red cell indices in patients with heart failure. European Journal of Heart Failure, 2018, 20, 114-122.	2.9	54
362	ESPEN Guidelines on Parenteral Nutrition: On Cardiology and Pneumology. Clinical Nutrition, 2009, 28, 455-460.	2.3	53
363	Immune and inflammation responses to a 3-day period of intensified running versus cycling. Brain, Behavior, and Immunity, 2014, 39, 180-185.	2.0	53
364	Impaired hepatoâ€renal function defined by the MELD XI score as prognosticator in acute heart failure. European Journal of Heart Failure, 2016, 18, 1518-1521.	2.9	53
365	Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. International Journal of Cardiology, 2016, 224, 231-239.	0.8	53
366	A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure. European Journal of Heart Failure, 2017, 19, 1310-1320.	2.9	53
367	Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on Acute Admissions at the Emergency and Cardiology Departments Across Europe. American Journal of Medicine, 2021, 134, 482-489.	0.6	53
368	Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. Circulation, 2022, 146, 438-449.	1.6	53
369	Aetiology and pathophysiological implications of oscillatory ventilation at rest and during exercise in chronic heart failure. Do Cheyne and Stokes have an important message for modern-day patients with heart failure?. European Heart Journal, 1999, 20, 946-953.	1.0	52
370	Relations between professional medical associations and the health-care industry, concerning scientific communication and continuing medical education: a Policy Statement from the European Society of Cardiology. European Heart Journal, 2012, 33, 666-674.	1.0	52
371	Dissociation between blood pressure and heart rate response to hypoxia after bilateral carotid body removal in men with systolic heart failure. Experimental Physiology, 2014, 99, 552-561.	0.9	52
372	Urinary levels of novel kidney biomarkers and risk of true worsening renal function and mortality in patients with acute heart failure. European Journal of Heart Failure, 2017, 19, 760-767.	2.9	52
373	Empagliflozin Improves Cardiovascular and Renal Outcomes in HeartÂFailure Irrespective of Systolic Blood Pressure. Journal of the American College of Cardiology, 2021, 78, 1337-1348.	1.2	52
374	Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. Heart Failure Reviews, 2013, 18, 107-122.	1.7	51
375	Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	51
376	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction. Circulation, 2020, 142, 1623-1632.	1.6	51
377	Silver paper: The future of health promotion and preventive actions, basic research, and clinical aspects of age-related disease. Aging Clinical and Experimental Research, 2009, 21, 376-385.	1.4	50
378	Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIRâ€HF trial: an analysis for the UK. European Journal of Heart Failure, 2012, 14, 782-790.	2.9	50

#	Article	IF	CITATIONS
379	Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment. European Journal of Heart Failure, 2020, 22, 1147-1155.	2.9	50
380	Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. Diabetes Care, 2021, 44, 586-594.	4.3	50
381	Sexâ€specific acute heart failure phenotypes and outcomes from PROTECT. European Journal of Heart Failure, 2013, 15, 1374-1381.	2.9	49
382	Use of High-Sensitivity Troponin T to IdentifyÂPatients With Acute Heart Failure atÂLowerÂRisk for Adverse Outcomes. JACC: Heart Failure, 2016, 4, 591-599.	1.9	49
383	Patient journey after admission for acute heart failure: length of stay, 30â€day readmission and 90â€day mortality. European Journal of Heart Failure, 2016, 18, 1041-1050.	2.9	49
384	Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the <scp>PROTECT</scp> trial. European Journal of Heart Failure, 2015, 17, 109-118.	2.9	48
385	Corrigendum to â€~ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008'[Eur Heart J 2008;29:2388–2442 and Eur J Heart Fail 2008;10:933–989]. European Heart Journal, 2008, 29, 3069-3069.	1.0	47
386	Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. European Heart Journal, 2018, 39, 3867-3875.	1.0	47
387	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: <scp>GALACTICâ€HF</scp> baseline characteristics and comparison with contemporary clinical trials. European Journal of Heart Failure, 2020, 22, 2160-2171.	2.9	47
388	Biomarkers in kidney and heart disease. Nephrology Dialysis Transplantation, 2011, 26, 62-74.	0.4	46
389	Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH multinational study. European Journal of Heart Failure, 2012, 14, 22-31.	2.9	46
390	Design of the remedē System Pivotal Trial: A Prospective, Randomized Study in the Use of Respiratory Rhythm Management to Treat Central Sleep Apnea. Journal of Cardiac Failure, 2015, 21, 892-902.	0.7	46
391	High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality. European Journal of Heart Failure, 2021, 23, 919-932.	2.9	46
392	Physician-Determined Worsening Heart Failure: A Novel Definition for Early Worsening Heart Failure in Patients Hospitalized for Acute Heart Failure – Association with Signs and Symptoms, Hospitalization Duration, and 60-Day Outcomes. Cardiology, 2010, 115, 29-36.	0.6	45
393	Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction. ESC Heart Failure, 2019, 6, 62-69.	1.4	45
394	Origin of Oscillatory Kinetics of Respiratory Gas Exchange in Chronic Heart Failure. Circulation, 1999, 100, 1065-1070.	1.6	44
395	Worsening Heart Failure Following Admission for Acute Heart Failure. JACC: Heart Failure, 2015, 3, 395-403.	1.9	44
396	Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure. Stroke, 2016, 47, 2031-2037.	1.0	44

23

#	Article	IF	CITATIONS
397	Novel endotypes in heart failure: effects on guideline-directed medical therapy. European Heart Journal, 2018, 39, 4269-4276.	1.0	44
398	Clinical Predictors and Hemodynamic Consequences of Elevated Peripheral Chemosensitivity in Optimally Treated Men With Chronic Systolic Heart Failure. Journal of Cardiac Failure, 2013, 19, 408-415.	0.7	43
399	Transvenous stimulation of the phrenic nerve for the treatment of central sleep apnoea: 12 months' experience with the remedē <sup>®</sup> System. European Journal of Heart Failure, 2016, 18, 1386-1393.	2.9	43
400	The PCSK9-LDL Receptor Axis andÂOutcomes in Heart Failure. Journal of the American College of Cardiology, 2017, 70, 2128-2136.	1.2	43
401	Clinical correlates and prognostic impact of impaired iron storage versus impaired iron transport in an international cohort of 1821 patients with chronic heart failure. International Journal of Cardiology, 2017, 243, 360-366.	0.8	42
402	Rationale and design of the AFFIRMâ€AHF trial: a randomised, doubleâ€blind, placeboâ€controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in ironâ€deficient patients admitted for acute heart failure. European Journal of Heart Failure, 2019, 21, 1651-1658.	2.9	42
403	Distance covered during a six-minute walk test predicts long-term cardiovascular mortality and hospitalisation rates in men with systolic heart failure: an observational study. Journal of Physiotherapy, 2013, 59, 177-187.	0.7	41
404	Resting and exercise haemodynamics in relation to sixâ€minute walk test in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2018, 20, 715-722.	2.9	41
405	Molecular Changes in Myocardium in the Course of Anemia or Iron Deficiency. Heart Failure Clinics, 2010, 6, 295-304.	1.0	40
406	Gonadal and adrenal androgen deficiencies as independent predictors of increased cardiovascular mortality in men with type II diabetes mellitus and stable coronary artery disease. International Journal of Cardiology, 2010, 143, 343-348.	0.8	40
407	The Safety of an Adenosine A1-Receptor Antagonist, Rolofylline, in Patients with Acute Heart Failure and Renal Impairment. Drug Safety, 2012, 35, 233-244.	1.4	40
408	Long-term efficacy and safety of phrenic nerve stimulation for the treatment of central sleep apnea. Sleep, 2019, 42, .	0.6	40
409	Rationale and design of the EMPERIALâ€Preserved and EMPERIALâ€Reduced trials of empagliflozin in patients with chronic heart failure. European Journal of Heart Failure, 2019, 21, 932-942.	2.9	40
410	Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes and Endocrinology,the, 2022, 10, 24-34.	5.5	40
411	Impaired baroreflex sensitivity and sympathovagal balance in syndrome X. American Journal of Cardiology, 1998, 82, 862-868.	0.7	39
412	Effect of altering conditions of the sequence method on baroreflex sensitivity. Journal of Hypertension, 2001, 19, 1279-1287.	0.3	39
413	Comparison of invasive and non-invasive measurements of haemodynamic parameters in patients with advanced heart failure. Journal of Cardiovascular Medicine, 2011, 12, 773-778.	0.6	39
414	Predictors of early dyspnoea relief in acute heart failure and the association with 30â€day outcomes: findings from ASCENDâ€HF. European Journal of Heart Failure, 2013, 15, 456-464.	2.9	39

#	Article	IF	CITATIONS
415	Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH) Tj ETQq1 1	0.784314	rgBT/Overloo
416	Depleted iron stores are associated with inspiratory muscle weakness independently of skeletal muscle mass in men with systolic chronic heart failure. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 547-556.	2.9	39
417	The impact of cachexia on cardiorespiratory reflex control in chronic heart failure. European Heart Journal, 1999, 20, 1667-1675.	1.0	38
418	The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina. Clinical Research in Cardiology, 2012, 101, 585-591.	1.5	38
419	Benefit of Warfarin Compared With Aspirin in Patients With Heart Failure in Sinus Rhythm. Circulation: Heart Failure, 2013, 6, 988-997.	1.6	38
420	Rationale and design of the CONFIRMâ€HF study: a doubleâ€blind, randomized, placeboâ€controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. ESC Heart Failure, 2014, 1, 52-58.	1.4	38
421	Liver Function, In-Hospital, and Post-Discharge Clinical Outcome in Patients With Acute Heart Failure—Results From the Relaxin for the Treatment of Patients With Acute Heart Failure Study. Journal of Cardiac Failure, 2014, 20, 407-413.	0.7	38
422	Patogenia y presentación clÃnica de la insuficiencia cardiaca aguda. Revista Espanola De Cardiologia, 2015, 68, 331-337.	0.6	38
423	Bone marrow iron depletion is common in patients with coronary artery disease. International Journal of Cardiology, 2015, 182, 517-522.	0.8	38
424	2016 ESC and ACC/AHA/HFSA heart failure guideline update — what is new and why is it important?. Nature Reviews Cardiology, 2016, 13, 623-628.	6.1	38
425	Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure. Journal of Clinical Pharmacology, 2017, 57, 440-451.	1.0	38
426	Effectiveness of screening for atrial fibrillation and its determinants. A meta-analysis. PLoS ONE, 2019, 14, e0213198.	1.1	38
427	Could the two-minute step test be an alternative to the six-minute walk test for patients with systolic heart failure?. European Journal of Preventive Cardiology, 2016, 23, 1307-1313.	0.8	37
428	Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. European Journal of Heart Failure, 2021, 23, 527-540.	2.9	37
429	Standardizing care for acute decompensated heart failure in a large megatrial: The approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). American Heart Journal, 2009, 157, 219-228.	1.2	36
430	Normal electrocardiographic and echocardiographic (M-mode and two-dimensional) values in Polish Landrace pigs. Acta Veterinaria Scandinavica, 2014, 56, 54.	0.5	36
431	Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. European Journal of Heart Failure, 2021, 23, 1662-1672.	2.9	36
432	ADQI 7: the clinical management of the Cardio-Renal syndromes: work group statements from the 7th ADQI consensus conference. Nephrology Dialysis Transplantation, 2010, 25, 2077-2089.	0.4	35

#	Article	IF	CITATIONS
433	Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	35
434	MicroRNAs relate to early worsening of renal function in patients with acute heart failure. International Journal of Cardiology, 2016, 203, 564-569.	0.8	35
435	Iron Therapy in Patients with Heart Failure and Iron Deficiency: Review of Iron Preparations for Practitioners. American Journal of Cardiovascular Drugs, 2017, 17, 183-201.	1.0	35
436	Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure. Journal of the American College of Cardiology, 2018, 71, 386-398.	1.2	35
437	Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. Circulation, 2021, 143, 1962-1972.	1.6	35
438	Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the <scp>VICTORIA</scp> trial. European Journal of Heart Failure, 2021, 23, 1300-1312.	2.9	35
439	Consequences of peripheral chemoreflex inhibition with lowâ€dose dopamine in humans. Journal of Physiology, 2014, 592, 1295-1308.	1.3	34
440	Clinical Profile and Prognostic Value of Anemia at the Time of Admission and Discharge Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2014, 7, 401-408.	1.6	34
441	Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. International Journal of Cardiology, 2016, 204, 164-171.	0.8	34
442	Plasma biomarkers to predict or rule out early postâ€discharge events after hospitalization for acute heart failure. European Journal of Heart Failure, 2017, 19, 728-738.	2.9	34
443	Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with midâ€range and preserved ejection fraction. European Journal of Heart Failure, 2017, 19, 1690-1697.	2.9	34
444	Safety, Tolerability and efficacy of Rapid Optimization, helped by NTâ€proBNP and GDFâ€15, of Heart Failure therapies (STRONGâ€HF): rationale and design for a multicentre, randomized, parallelâ€group study. European Journal of Heart Failure, 2019, 21, 1459-1467.	2.9	34
445	Identification of Chronic Heart Failure Patients with a High 12-Month Mortality Risk Using Biomarkers Including Plasma C-Terminal Pro-Endothelin-1. PLoS ONE, 2011, 6, e14506.	1.1	34
446	Cardiac autonomic dysfunction in AIDS is not secondary to heart failure. International Journal of Cardiology, 2000, 74, 133-137.	0.8	33
447	Anemia in chronic heart failure: Can we treat? What to treat?. Heart Failure Reviews, 2012, 17, 203-210.	1.7	33
448	Rationale and Design of the VITALITY-HFpEF Trial. Circulation: Heart Failure, 2019, 12, e005998.	1.6	33
449	Central and Peripheral Determinants of Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction. JACC: Heart Failure, 2019, 7, 321-332.	1.9	33
450	Clinical value of preâ€discharge bioâ€adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission. European Journal of Heart Failure, 2020, 22, 683-691.	2.9	33

#	Article	IF	CITATIONS
451	Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the <scp>DAPAâ€HF</scp> trial. European Journal of Heart Failure, 2021, 23, 601-613.	2.9	33
452	Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from <scp>DAPAâ€HF</scp> . European Journal of Heart Failure, 2022, 24, 513-525.	2.9	33
453	The association of lower testosterone level with coronary artery disease in postmenopausal women. International Journal of Cardiology, 2003, 87, 53-57.	0.8	32
454	Exercise programs for LVAD supported patients: A snapshot from the ESC affiliated countries. International Journal of Cardiology, 2015, 201, 215-219.	0.8	32
455	Plasma kidney injury moleculeâ€1 in heart failure: renal mechanisms and clinical outcome. European Journal of Heart Failure, 2016, 18, 641-649.	2.9	32
456	A combined clinical and biomarker approach to predict diuretic response in acute heart failure. Clinical Research in Cardiology, 2016, 105, 145-153.	1.5	32
457	The year in cardiology 2018: heart failure. European Heart Journal, 2019, 40, 651-661.	1.0	32
458	Multiâ€organ dysfunction/injury on admission identifies acute heart failure patients at high risk of poor outcome. European Journal of Heart Failure, 2019, 21, 744-750.	2.9	32
459	Structural and functional abnormalities in iron-depleted heart. Heart Failure Reviews, 2019, 24, 269-277.	1.7	32
460	Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies highâ€risk acute heart failure patients. European Journal of Heart Failure, 2021, 23, 729-739.	2.9	32
461	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. Annals of Internal Medicine, 2021, 174, 1065-1072.	2.0	32
462	Impact of mitral regurgitation in patients with worsening heart failure: insights from <scp>BIOSTATâ€CHF</scp> . European Journal of Heart Failure, 2021, 23, 1750-1758.	2.9	32
463	<scp>COVID</scp> â€19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 1806-1818.	2.9	32
464	Reproducibility of Heart Rate Variability Measures in Patients with Chronic Heart Failure. Clinical Science, 1996, 91, 391-398.	1.8	31
465	Deficiencies in circulating testosterone and dehydroepiandrosterone sulphate, and depression in men with systolic chronic heart failure. European Journal of Heart Failure, 2010, 12, 966-973.	2.9	31
466	Prevention of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrology Dialysis Transplantation, 2010, 25, 1777-1784.	0.4	31
467	GuÃa de práctica clÃnica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. Revista Espanola De Cardiologia, 2012, 65, 938.e1-938.e59.	0.6	31
468	Rationale for and design of the <scp>TRUEâ€AHF</scp> trial: the effects of ularitide on the shortâ€ŧerm clinical course and longâ€ŧerm mortality of patients with acute heart failure. European Journal of Heart Failure, 2017, 19, 673-681.	2.9	31

#	Article	IF	CITATIONS
469	Comparison between spectral analysis and the phenylephrine method for the assessment of baroreflex sensitivity in chronic heart failure. Clinical Science, 1999, 97, 503-513.	1.8	30
470	Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS-III. European Journal of Heart Failure, 2004, 6, 493-500.	2.9	30
471	Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis. International Journal of Cardiology, 2013, 168, 3878-3883.	0.8	30
472	Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fractionâ€. European Journal of Heart Failure, 2013, 15, 679-689.	2.9	30
473	Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure. Journal of Cardiac Failure, 2017, 23, 231-239.	0.7	30
474	Sustained 12 Month Benefit of Phrenic Nerve Stimulation for Central Sleep Apnea. American Journal of Cardiology, 2018, 121, 1400-1408.	0.7	30
475	Proteomic diversity of highâ€density lipoprotein explains its association with clinical outcome in patients with heart failure. European Journal of Heart Failure, 2018, 20, 260-267.	2.9	30
476	Transvenous Phrenic Nerve Stimulation for Treatment of Central Sleep Apnea: Five-Year Safety and Efficacy Outcomes. Nature and Science of Sleep, 2021, Volume 13, 515-526.	1.4	30
477	Rationale and design of a multicentre, randomized, placeboâ€controlled trial of mirabegron, a Beta3â€adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3â€left ventricular hypertrophy (Beta3â€LVH). ESC Heart Failure, 2018, 5, 830-841.	1.4	29
478	Efficacy and safety of sodium–glucose coâ€ŧransporter 2 inhibition according to left ventricular ejection fraction in DAPAâ€HF. European Journal of Heart Failure, 2020, 22, 1247-1258.	2.9	29
479	Transient autonomic dysfunction precedes ST-segment depression in patients with syndrome X. American Journal of Cardiology, 1996, 77, 942-947.	0.7	28
480	Hyperhomocysteinemia in patients with symptomatic chronic heart failure: Prevalence and prognostic importance—pilot study. Atherosclerosis, 2007, 194, 408-414.	0.4	28
481	Effects of selective carotid body stimulation with adenosine in conscious humans. Journal of Physiology, 2016, 594, 6225-6240.	1.3	28
482	Plasma proteomic approach in patients withÂheart failure: insights into pathogenesis ofÂdisease progression and potential novel treatment targets. European Journal of Heart Failure, 2020, 22, 70-80.	2.9	28
483	Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in <scp>DAPAâ€HF</scp> . European Journal of Heart Failure, 2022, 24, 1066-1076.	2.9	28
484	Effects of amiodarone on the P-wave triggered signal-averaged electrocardiogram in patients with paroxysmal atrial fibrillation and coronary artery disease. American Journal of Cardiology, 1999, 83, 112-114.	0.7	27
485	The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure. European Journal of Heart Failure, 2009, 11, 1071-1077.	2.9	27
486	Changes in autonomic balance in patients with decompensated chronic heart failure. Clinical Autonomic Research, 2011, 21, 47-54.	1.4	27

#	Article	IF	CITATIONS
487	The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIRâ€HF study. European Journal of Heart Failure, 2013, 15, 756-762.	2.9	27
488	Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF. Clinical Research in Cardiology, 2018, 107, 170-181.	1.5	27
489	Controlled decongestion by Reprieve therapy in acute heart failure: results of the TARGETâ€1 and TARGETâ€2 studies. European Journal of Heart Failure, 2019, 21, 1079-1087.	2.9	27
490	Vitamin B12and folate deficiency in chronic heart failure. Heart, 2015, 101, 302-310.	1.2	26
491	Hyperkalemia and Treatment With RAASÂInhibitors During Acute HeartÂFailure Hospitalizations and TheirÂAssociation With Mortality. JACC: Heart Failure, 2019, 7, 970-979.	1.9	26
492	Cognitive Decline Over Time in Patients With Systolic HeartÂFailure. JACC: Heart Failure, 2019, 7, 1042-1053.	1.9	26
493	Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2021, 6, 678.	3.0	26
494	Heart failure in COVIDâ€19: the multicentre, multinational PCHFâ€COVICAV registry. ESC Heart Failure, 2021, 8, 4955-4967.	1.4	26
495	Heart rhythms, ventricular arrhythmias,and death in chronic heart failure. Journal of Cardiac Failure, 1996, 2, 177-183.	0.7	25
496	Home telemonitoring of vital signs and cardiorespiratory signals in heart failure patients: System architecture and feasibility of the HHH model. International Journal of Cardiology, 2007, 120, 371-379.	0.8	25
497	<scp>CHA<sub>2</sub>DS<sub>2</sub>â€VASc</scp> score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm. European Journal of Heart Failure, 2016, 18, 1261-1266.	2.9	25
498	Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment. ESC Heart Failure, 2018, 5, 800-808.	1.4	25
499	Prediction of AF in HeartÂFailure With Preserved Ejection Fraction. JACC: Cardiovascular Imaging, 2021, 14, 131-144.	2.3	25
500	Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (REDâ€HF). European Journal of Heart Failure, 2013, 15, 334-341.	2.9	24
501	Recurrent Stroke in the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial. Cerebrovascular Diseases, 2014, 38, 176-181.	0.8	24
502	Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial. European Journal of Heart Failure, 2015, 17, 697-706.	2.9	24
503	What does the lay public know about heart failure? Findings from the Heart Failure Awareness Day Initiative. European Journal of Heart Failure, 2016, 18, 66-70.	2.9	24
504	Effects of serelaxin in patients admitted for acute heart failure: a metaâ€analysis. European Journal of Heart Failure, 2020, 22, 315-329.	2.9	24

#	Article	IF	CITATIONS
505	Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of <scp>DAPAâ€HF</scp> . European Journal of Heart Failure, 2021, 23, 632-643.	2.9	24
506	Expression and Complex Formation of MMP9, MMP2, NGAL, and TIMP1 in Porcine Myocardium but Not in Skeletal Muscles in Male Pigs with Tachycardia-Induced Systolic Heart Failure. BioMed Research International, 2013, 2013, 1-12.	0.9	23
507	Heart Failure in Patients With Atrial Fibrillation Is Associated With a High Symptom and Hospitalization Burden: The <scp>RealiseAF</scp> Survey. Clinical Cardiology, 2013, 36, 766-774.	0.7	23
508	Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational costâ€effectiveness analysis utilising <scp>AFFIRMâ€AHF</scp> . European Journal of Heart Failure, 2021, 23, 1687-1697.	2.9	23
509	Liver function tests in patients with acute heart failure. Polish Archives of Internal Medicine, 2012, 122, 471-479.	0.3	23
510	Effects of an outpatient intervention comprising nurseâ€led nonâ€invasive assessments, telemedicine support and remote cardiologists' decisions in patients with heart failure ( <scp>AMULET</scp> study): a randomised controlled trial. European Journal of Heart Failure, 2022, 24, 565-577.	2.9	23
511	The Effects of Adenosine A1 Receptor Antagonism in Patients With Acute Decompensated Heart Failure and Worsening Renal Function: The REACH UP Study. Journal of Cardiac Failure, 2010, 16, 714-719.	0.7	22
512	Effects of ivabradine in patients with stable angina receiving beta-blockers according to baseline heart rate: an analysis of the ASSOCIATE study. International Journal of Cardiology, 2013, 168, 789-794.	0.8	22
513	European Cardiac Resynchronization Therapy Survey II: rationale and design. Europace, 2015, 17, 137-141.	0.7	22
514	Hepatorenal dysfunction identifies highâ€risk patients with acute heart failure: insights from the RELAXâ€AHF trial. ESC Heart Failure, 2019, 6, 1188-1198.	1.4	22
515	Navigating between Scylla and Charybdis: challenges and strategies for implementing guidelineâ€directed medical therapy in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2021, 23, 1999-2007.	2.9	22
516	Very-low-frequency oscillations in heart rate and blood pressure in periodic breathing: role of the cardiovascular limb of the hypoxic chemoreflex. Clinical Science, 2000, 99, 125-132.	1.8	21
517	Echocardiographic determinants of mortality in patients >67 years of age with chronic heart failure. American Journal of Cardiology, 2000, 86, 158-161.	0.7	21
518	Circulating testosterone and estradiol, autonomic balance and baroreflex sensitivity in middle-aged and elderly men with heart failure. Aging Male, 2013, 16, 58-66.	0.9	21
519	Quality of Anticoagulation Control in Preventing Adverse Events in Patients With Heart Failure in Sinus Rhythm. Circulation: Heart Failure, 2015, 8, 504-509.	1.6	21
520	Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. European Journal of Heart Failure, 2016, 18, 672-683.	2.9	21
521	Cardiovascular stress biomarker assessment of middle-aged non-athlete marathon runners. European Journal of Preventive Cardiology, 2019, 26, 318-327.	0.8	21
522	Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAXâ€AHFâ€2 trial. European Journal of Heart Failure, 2020, 22, 726-738.	2.9	21

#	Article	IF	CITATIONS
523	Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). Circulation, 2021, 144, 1489-1499.	1.6	21
524	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. Circulation: Heart Failure, 2021, 14, CIRCHEARTFAILURE121008837.	1.6	21
525	Empagliflozin Improves Outcomes inÂPatients With HeartÂFailure and Preserved Ejection Fraction Irrespective of Age. Journal of the American College of Cardiology, 2022, 80, 1-18.	1.2	21
526	Activation of the NF-κB system in peripheral blood leukocytes from patients with chronic heart failure. European Journal of Heart Failure, 2005, 7, 984-990.	2.9	20
527	Japanese-Western Consensus Meeting on Biomarkers. International Heart Journal, 2011, 52, 253-265.	0.5	20
528	Temporal trends in secondary prevention in myocardial infarction patients discharged with left ventricular systolic dysfunction in Poland. European Journal of Preventive Cardiology, 2018, 25, 960-969.	0.8	20
529	Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry. ESC Heart Failure, 2021, 8, 861-871.	1.4	20
530	Guidance on the management of left ventricular assist device <scp>(LVAD)</scp> supported patients for the nonâ€ <scp>LVAD</scp> specialist healthcare provider: executive summary. European Journal of Heart Failure, 2021, 23, 1597-1609.	2.9	20
531	Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. Clinical Research in Cardiology, 2020, 109, 1048-1059.	1.5	20
532	Both iron excess and iron depletion impair viability of rat H9C2 cardiomyocytes and L6G8C5 myocytes. Kardiologia Polska, 2017, 75, 267-275.	0.3	20
533	Clinical, respiratory, haemodynamic, and metabolic determinants of lactate in heart failure. Kardiologia Polska, 2019, 77, 47-52.	0.3	20
534	Additional burden of iron deficiency in heart failure patients beyond the cardioâ€renal anaemia syndrome: findings from the <scp>BIOSTATâ€CHF</scp> study. European Journal of Heart Failure, 2022, 24, 192-204.	2.9	20
535	Impact of periodic breathing on measurement of oxygen uptake and respiratory exchange ratio during cardiopulmonary exercise testing. Clinical Science, 2002, 103, 543-552.	1.8	19
536	Rationale and Design of a Prospective Trial to Assess the Sensitivity and Positive Predictive Value of Implantable Intrathoracic Impedance Monitoring in the Prediction of Heart Failure Hospitalizations: The SENSE-HF Study. Journal of Cardiac Failure, 2009, 15, 394-400.	0.7	19
537	Development of porcine model of chronic tachycardia-induced cardiomyopathy. International Journal of Cardiology, 2011, 153, 36-41.	0.8	19
538	RHYTHM-AF: design of an international registry on cardioversion of atrial fibrillation and characteristics of participating centers. BMC Cardiovascular Disorders, 2012, 12, 85.	0.7	19
539	Health locus of control and the sense of self-efficacy in patients with systolic heart failure: a pilot study. Patient Preference and Adherence, 2013, 7, 337.	0.8	19
540	Effect of ferric carboxymaltose on calculated plasma volume status and clinical congestion: a FAIRâ€HF substudy. ESC Heart Failure, 2019, 6, 621-628.	1.4	19

#	Article	IF	CITATIONS
541	Is acute heart failure a distinctive disorder? An analysis from BIOSTAT HF. European Journal of Heart Failure, 2021, 23, 43-57.	2.9	19
542	Comparison between spectral analysis and the phenylephrine method for the assessment of baroreflex sensitivity in chronic heart failure. Clinical Science, 1999, 97, 503.	1.8	18
543	Pathophysiological and clinical relevance of simplified monitoring of nocturnal breathing disorders in heart failure patients. European Journal of Heart Failure, 2009, 11, 264-272.	2.9	18
544	Value of serum pregnancy-associated plasma protein A for predicting cardiovascular events among patients presenting with cardiac chest pain. Cmaj, 2013, 185, E295-E303.	0.9	18
545	Elevated lactate in acute heart failure patients with intracellular iron deficiency as identifier of poor outcome. Kardiologia Polska, 2019, 77, 347-354.	0.3	18
546	Low Lymphocyte Ratio as a Novel Prognostic Factor in Acute Heart Failure: Results from the Pre-RELAX-AHF Study. Cardiology, 2010, 117, 190-196.	0.6	17
547	New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. European Journal of Heart Failure, 2017, 19, 718-727.	2.9	17
548	Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study. Clinical Research in Cardiology, 2017, 106, 280-292.	1.5	17
549	Plasma Neutrophil Gelatinase-Associated Lipocalin and Predicting Clinically Relevant Worsening Renal Function in Acute Heart Failure. International Journal of Molecular Sciences, 2017, 18, 1470.	1.8	17
550	Acute heart failure: lessons learned, roads ahead. European Journal of Heart Failure, 2018, 20, 842-850.	2.9	17
551	Effects of a Novel Nitroxyl Donor in Acute HeartÂFailure. JACC: Heart Failure, 2021, 9, 146-157.	1.9	17
552	Oxygenation pattern and compensatory responses to hypoxia and hypercapnia following bilateral carotid body resection in humans. Journal of Physiology, 2021, 599, 2323-2340.	1.3	17
553	Spot urine sodium in acute heart failure: differences in prognostic value on admission and discharge. ESC Heart Failure, 2021, 8, 2597-2602.	1.4	17
554	Reproducibility of Heart Rate Variability Indices daring Exercise Stress Testing and Inotrope Infusion in Chronic Heart Failure Patients. Clinical Science, 1996, 91, 87-88.	0.0	16
555	Excessive ventilation during early phase of exercise: A new predictor of poor longâ€ŧerm outcome in patients with chronic heart failure. European Journal of Heart Failure, 2007, 9, 1024-1031.	2.9	16
556	Rationale and Design of the Hemodynamic, Echocardiographic and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: A Randomized Controlled Trial in Patients Hospitalized With Heart Failure (HORIZON-HF) Trial. American Journal of Therapeutics, 2008, 15, 231-240.	0.5	16
557	Anemia in heart failure: an overview of current concepts. Future Cardiology, 2011, 7, 119-129.	0.5	16
558	Pathogenesis and Clinical Presentation of Acute Heart Failure. Revista Espanola De Cardiologia (English Ed ), 2015, 68, 331-337.	0.4	16

#	Article	lF	CITATIONS
559	Influence of the availability of iron during hypoxia on the genes associated with apoptotic activity and local iron metabolism in rat H9C2 cardiomyocytes and L6G8C5 skeletal myocytes. Molecular Medicine Reports, 2016, 14, 3969-3977.	1.1	16
560	Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. Clinical Research in Cardiology, 2016, 105, 727-737.	1.5	16
561	Coronary angiography in worsening heart failure: determinants, findings and prognostic implications. Heart, 2018, 104, 606-613.	1.2	16
562	Trajectories of Changes in Renal Function in Patients with Acute Heart Failure. Journal of Cardiac Failure, 2019, 25, 866-874.	0.7	16
563	Compensatory post-diuretic renal sodium reabsorption is not a dominant mechanism of diuretic resistance in acute heart failure. European Heart Journal, 2021, 42, 4468-4477.	1.0	16
564	Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. European Journal of Heart Failure, 2022, 24, 782-790.	2.9	16
565	Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function. European Journal of Heart Failure, 2010, 12, 1238-1246.	2.9	15
566	Effect on Mode of Death of Heart Failure Treatment Started with Bisoprolol Followed by Enalapril, Compared to the Opposite Order: Results of the Randomized CIBIS III Trial. Cardiovascular Therapeutics, 2011, 29, 89-98.	1.1	15
567	Cognitive Function in Ambulatory Patients with Systolic Heart Failure: Insights from the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial. PLoS ONE, 2014, 9, e113447.	1.1	15
568	Higher serum phosphorus is associated with catabolic/anabolic imbalance in heart failure. Journal of Cachexia, Sarcopenia and Muscle, 2015, 6, 325-334.	2.9	15
569	A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain. Revista Espanola De Cardiologia (English Ed ), 2015, 68, 846-851.	0.4	15
570	Iron Depletion Affects Genes Encoding Mitochondrial Electron Transport Chain and Genes of NonÂOxidative Metabolism, Pyruvate Kinase and Lactate Dehydrogenase, in Primary Human Cardiac Myocytes Cultured upon Mechanical Stretch. Cells, 2018, 7, 175.	1.8	15
571	Genetic risk and atrial fibrillation in patients with heart failure. European Journal of Heart Failure, 2020, 22, 519-527.	2.9	15
572	Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency. European Journal of Heart Failure, 2022, 24, 821-832.	2.9	15
573	Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial. European Journal of Heart Failure, 2022, 24, 1614-1622.	2.9	15
574	Nuclear factor-kappaB activity in peripheral blood mononuclear cells in cachectic and non-cachectic patients with chronic heart failure. International Journal of Cardiology, 2007, 122, 111-116.	0.8	14
575	Actualización detallada de las guÃas de la ESC para el manejo de la fibrilación auricular de 2012. Revista Espanola De Cardiologia, 2013, 66, 54.e1-54.e24.	0.6	14
576	Could gonadal and adrenal androgen deficiencies contribute to the depressive symptoms in men with systolic heart failure?. Aging Male, 2016, 19, 221-230.	0.9	14

#	Article	IF	CITATIONS
577	Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure. Circulation: Heart Failure, 2020, 13, e007879.	1.6	14
578	The influence of metformin and the presence of type 2 diabetes mellitus on mortality and hospitalisation in patients with heart failure. Kardiologia Polska, 2018, 76, 1336-1343.	0.3	14
579	Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. European Heart Journal, 2022, 43, 863-867.	1.0	14
580	Role of catecholamines and sympathetic activation as a risk factor for coronary artery disease. European Journal of Cardiovascular Prevention and Rehabilitation, 1995, 2, 222-228.	1.5	13
581	Lack of decrease in plasma N-terminal pro-brain natriuretic peptide identifies acute heart failure patients with very poor outcome. International Journal of Cardiology, 2008, 129, 373-378.	0.8	13
582	European silver paper on the future of health promotion and preventive actions, basic research, and clinical aspects of age-related disease. European Journal of Ageing, 2009, 6, 51-57.	1.2	13
583	Erythropoietin levels in heart failure after an acute myocardial infarction: Determinants, prognostic value, and the effects of captopril versus losartan. American Heart Journal, 2009, 157, 91-96.	1.2	13
584	The first prognostic model for stroke and death in patients with systolic heart failure. Journal of Cardiology, 2016, 68, 100-103.	0.8	13
585	Elevated troponin I level assessed by a new high-sensitive assay and the risk of poor outcomes in patients with acute heart failure. International Journal of Cardiology, 2017, 230, 646-652.	0.8	13
586	Sleep disordered breathing in patients with heart failure. Cardiology Journal, 2013, 20, 345-355.	0.5	13
587	On the search for the right definition of heart failure with preserved ejection fraction. Cardiology Journal, 2020, 27, 449-468.	0.5	13
588	Biomarkers of Myocardial Injury and Remodeling in Heart Failure. Journal of Personalized Medicine, 2022, 12, 799.	1.1	13
589	ESC Guidelines for the Diagnosis And Treatment of Acute And Chronic Heart Failure 2008. Revista Espanola De Cardiologia (English Ed ), 2008, 61, 1329.	0.4	12
590	Permutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHF. Clinical Research in Cardiology, 2011, 100, 745-753.	1.5	12
591	Mid-regional pro-adrenomedullin improves disposition strategies for patients with acute dyspnoea: results from the BACH trial. Emergency Medicine Journal, 2013, 30, 633-637.	0.4	12
592	Relation of Longitudinal Changes in Quality of Life Assessments to Changes in Functional Capacity in Patients With Heart Failure With and Without Anemia. American Journal of Cardiology, 2016, 117, 1482-1487.	0.7	12
593	Relationship between central sleep apnea and Cheyneâ^'Stokes Respiration. International Journal of Cardiology, 2016, 206, S8-S12.	0.8	12
594	Iron limitation promotes the atrophy of skeletal myocytes, whereas iron supplementation prevents this process in the hypoxic conditions. International Journal of Molecular Medicine, 2018, 41, 2678-2686.	1.8	12

#	Article	IF	CITATIONS
595	Patterns of dyspnoea onset in patients with acute heart failure: clinical and prognostic implications. ESC Heart Failure, 2019, 6, 16-26.	1.4	12
596	Cause of Death in Patients With AcuteÂHeartÂFailure. JACC: Heart Failure, 2020, 8, 999-1008.	1.9	12
597	Elevated plasma endothelinâ€1 is related to low natriuresis, clinical signs of congestion, and poor outcome in acute heart failure. ESC Heart Failure, 2020, 7, 3536-3544.	1.4	12
598	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction. JAMA Cardiology, 2021, 6, 1298-1305.	3.0	12
599	Could an analysis of mean corpuscular volume help to improve risk stratification in non-anemic patients with acute myocardial infarction?. Cardiology Journal, 2015, 22, 421-427.	0.5	12
600	Distinct renin/aldosterone activity profiles correlate with renal function, natriuretic response, decongestive ability and prognosis in acute heart failure. International Journal of Cardiology, 2021, 345, 54-60.	0.8	12
601	Long-term time-course of nocturnal breathing disorders in heart failure patients. European Respiratory Journal, 2010, 35, 361-367.	3.1	11
602	Acute Heart Failure Clinical Drug Development: From Planning to Proof of Activity to Phase III. Cardiology, 2010, 116, 292-301.	0.6	11
603	Acute heart failure in the young: Clinical characteristics and biomarker profiles. International Journal of Cardiology, 2016, 221, 1067-1072.	0.8	11
604	Clinical and Echocardiographic Factors Associated With New-Onset Atrial Fibrillation in Heart Failure – Subanalysis of the WARCEF Trial –. Circulation Journal, 2016, 80, 619-626.	0.7	11
605	Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure. Circulation: Heart Failure, 2017, 10, .	1.6	11
606	Evaluation of Skeletal Muscle Function and Effects of Early Rehabilitation during Acute Heart Failure: Rationale and Study Design. BioMed Research International, 2018, 2018, 1-8.	0.9	11
607	Hypoxic tachycardia is not a result of increased respiratory activity in healthy subjects. Experimental Physiology, 2019, 104, 476-489.	0.9	11
608	Assessment of baroreflex sensitivity has no prognostic value in contemporary, optimally managed patients with mildâ€toâ€moderate heart failure with reduced ejection fraction: a retrospective analysis of 5â€year survival. European Journal of Heart Failure, 2019, 21, 50-58.	2.9	11
609	Megaâ€ŧrials in heart failure: effects of dilution in examination of new therapies. European Journal of Heart Failure, 2020, 22, 1698-1707.	2.9	11
610	Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients. European Journal of Heart Failure, 2021, 23, 1677-1686.	2.9	11
611	Population of Polish patients participating in the Heart Failure Pilot Survey (ESC-HF Pilot). Kardiologia Polska, 2013, 71, 234-240.	0.3	11
612	P-wave signal-averaged electrocardiogram in patients with idiopathic mitral valve prolapse syndrome and supraventricular arrhythmias. International Journal of Cardiology, 1995, 50, 175-180.	0.8	10

#	Article	lF	CITATIONS
613	Increased body fat is associated with potentiation of blood pressure response to hypoxia in healthy men: relations with insulin and leptin. Clinical Autonomic Research, 2016, 26, 107-116.	1.4	10
614	Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial. American Heart Journal, 2017, 190, 113-122.	1.2	10
615	Monitoring of iron status in patients with heart failure. European Heart Journal Supplements, 2019, 21, M32-M35.	0.0	10
616	Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation. Clinical Research in Cardiology, 2019, 108, 797-805.	1.5	10
617	Distinct clinical phenotypes of congestion in acute heart failure: characteristics, treatment response, and outcomes. ESC Heart Failure, 2020, 7, 3830-3840.	1.4	10
618	Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the <scp>RELAXâ€AHF</scp> â€⊋ study. European Journal of Heart Failure, 2021, 23, 58-67.	2.9	10
619	HFA of the ESC position paper on the management of LVADâ€supported patients for the nonâ€LVAD specialist healthcare provider Part 3: at the hospital and discharge. ESC Heart Failure, 2021, 8, 4425-4443.	1.4	10
620	Hospitalisation length and prognosis in heart failure patients. Kardiologia Polska, 2017, 75, 323-331.	0.3	10
621	Persistent hyperlactataemia is related to high rates of in-hospital adverse events and poor outcome in acute heart failure. Kardiologia Polska, 2019, 77, 355-362.	0.3	10
622	Costs of management of patients with coronary artery disease in Poland: the multicenter RECENT study. Polish Archives of Internal Medicine, 2012, 122, 599-607.	0.3	10
623	Efficacy of Dapagliflozin in Black Versus White Patients With HeartÂFailure and Reduced Ejection Fraction. JACC: Heart Failure, 2022, 10, 52-64.	1.9	10
624	Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure. Clinical Research in Cardiology, 2022, 111, 912-923.	1.5	10
625	Relationship of Dapagliflozin WithÂSerumÂSodium. JACC: Heart Failure, 2022, 10, 306-318.	1.9	10
626	Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial. Circulation: Heart Failure, 2022, 15, .	1.6	10
627	Very-low-frequency oscillations in heart rate and blood pressure in periodic breathing: role of the cardiovascular limb of the hypoxic chemoreflex. Clinical Science, 2000, 99, 125.	1.8	9
628	A multi-country randomised trial of the role of a new telemonitoring system in CHF: the HHH study (Home or Hospital in Heart Failure). Rational, study design and protocol. European Heart Journal Supplements, 2004, 6, F99-F102.	0.0	9
629	Cardiorenal Syndromes – Recommendations from Clinical Practice Guidelines: The Cardiologist's View. Contributions To Nephrology, 2010, 165, 145-152.	1.1	9
630	Stroke in Heart Failure in Sinus Rhythm: The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction Trial. Cerebrovascular Diseases, 2013, 36, 74-78.	0.8	9

#	Article	IF	CITATIONS
631	The influence of confounders in the analysis of mid-regional pro-atrial natriuretic peptide in patients with chronic heart failure. International Journal of Cardiology, 2016, 219, 84-91.	0.8	9
632	Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial. American Heart Journal, 2017, 187, 62-69.	1.2	9
633	Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLASTâ€AHF trial. European Journal of Heart Failure, 2019, 21, 1561-1570.	2.9	9
634	Heart rate and blood pressure monitoring in heart failure. European Heart Journal Supplements, 2019, 21, M13-M16.	0.0	9
635	Expression of sex steroid receptors and aromatase in adipose tissue in different body regions in men with coronary artery disease with and without ischemic systolic heart failure. Aging Male, 2020, 23, 141-153.	0.9	9
636	Comparison of left ventricular longitudinal systolic function parameters in the prediction of adverse outcome in heart failure with preserved ejection fraction. ESC Heart Failure, 2021, 8, 1531-1540.	1.4	9
637	Pathophysiology of Advanced Heart Failure. Heart Failure Clinics, 2021, 17, 519-531.	1.0	9
638	Enzyme replacement therapy in Fabry disease in Poland – position statement. Polish Archives of Internal Medicine, 2019, 130, 91-97.	0.3	9
639	Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure. European Journal of Heart Failure, 2022, 24, 308-320.	2.9	9
640	Minimally Clinically Important Difference in Health Status Scores inÂPatients With HFrEF vs HFpEF. JACC: Heart Failure, 2022, 10, 651-661.	1.9	9
641	The effect of digoxin on the serum potassium concentration. Scandinavian Journal of Clinical and Laboratory Investigation, 1993, 53, 187-189.	0.6	8
642	Impact of periodic breathing on and : a quantitative approach by Fourier analysis. Respiration Physiology, 1999, 118, 247-255.	2.8	8
643	EPO's rescue mission in acute myocardial infarction: still more hopes than evidence. European Heart Journal, 2010, 31, 2577-2579.	1.0	8
644	Anabolic deficiencies in men with systolic heart failure: do co-morbidities and therapies really contribute significantly?. Aging Male, 2013, 16, 123-131.	0.9	8
645	Comparison of clinical profile and management of outpatients with heart failure with reduced left ventricular ejection fraction treated by general practitioners and cardiologists in contemporary Poland: The results from the DATA-HELP registry. International Journal of Cardiology, 2014, 176, 852-858.	0.8	8
646	Clinical research Patients with heart failure and concomitant chronic obstructive pulmonary disease participating in the Heart Failure Pilot Survey (ESC-HF Pilot) – Polish population. Archives of Medical Science, 2015, 4, 743-750.	0.4	8
647	Iron deficiency in heart failure: Impact on response to cardiac resynchronization therapy. International Journal of Cardiology, 2016, 222, 133-134.	0.8	8
648	Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. Clinical Research in Cardiology, 2017, 106, 444-456.	1.5	8

#	Article	IF	CITATIONS
649	Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial. Cardiovascular Drugs and Therapy, 2017, 31, 281-293.	1.3	8
650	Nurseâ€led ambulatory care supported by nonâ€invasive haemodynamic assessment after acute heart failure decompensation. ESC Heart Failure, 2021, 8, 1018-1026.	1.4	8
651	Rationale and design of the AMULET study: A new Model of telemedical care in patients with heart failure. ESC Heart Failure, 2021, 8, 2569-2579.	1.4	8
652	Primary Human Cardiomyocytes and Cardiofibroblasts Treated with Sera from Myocarditis Patients Exhibit an Increased Iron Demand and Complex Changes in the Gene Expression. Cells, 2021, 10, 818.	1.8	8
653	Clinical Outcome Predictions for the VerlCiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. Journal of Cardiac Failure, 2021, 27, 949-956.	0.7	8
654	Amended <scp>STRONGâ€HF</scp> study design. European Journal of Heart Failure, 2021, 23, 1981-1982.	2.9	8
655	Adherence to systolic heart failure guidelines in ambulatory care in Poland – data from the international QUALIFY survey. Polish Archives of Internal Medicine, 2017, 127, 657-665.	0.3	8
656	Atrial fibrillation in outpatients with stable coronary artery disease : results from the multicenter RECENT study. Polish Archives of Internal Medicine, 2015, 125, 162-171.	0.3	8
657	Responder analysis for improvement in sixâ€minute walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency. European Journal of Heart Failure, 2022, , .	2.9	8
658	Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008970.	1.6	8
659	Novel Phenotyping for Acute Heart Failure—Unsupervised Machine Learning-Based Approach. Biomedicines, 2022, 10, 1514.	1.4	8
660	Role of Catecholamines and Sympathetic Activation as a Risk Factor for Coronary Artery Disease. European Journal of Cardiovascular Prevention and Rehabilitation, 1995, 2, 222-228.	3.1	7
661	GuÃa de práctica clÃnica para la valoración del riesgo cardiaco preoperatorio y el manejo cardiaco perioperatorio en la cirugÃa no cardiaca. Revista Espanola De Cardiologia, 2009, 62, 1467.e1-1467.e56.	0.6	7
662	Management of Chronic Cardiorenal Syndrome. Contributions To Nephrology, 2010, 165, 129-139.	1.1	7
663	Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin. American Journal of Cardiology, 2015, 116, 904-912.	0.7	7
664	Iron Deficiency Treatment in Patients with Heart Failure. Handbook of Experimental Pharmacology, 2017, 243, 561-576.	0.9	7
665	Effects of running a marathon on irisin concentration in men aged over 50. Journal of Physiological Sciences, 2019, 69, 79-84.	0.9	7
666	Association between mortality and implantable cardioverterâ€defibrillators by aetiology of heart failure: a propensityâ€matched analysis of the WARCEF trial. ESC Heart Failure, 2019, 6, 297-307.	1.4	7

#	Article	IF	CITATIONS
667	The Effects of a Marathon Effort on Psychomotor Performance and Catecholamine Concentration in Runners over 50 Years of Age. Applied Sciences (Switzerland), 2020, 10, 2067.	1.3	7
668	Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study. Clinical Research in Cardiology, 2020, 109, 967-977.	1.5	7
669	The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. Journal of Cardiac Failure, 2021, 27, 808-811.	0.7	7
670	Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist deviceâ€supported patients for the nonâ€left ventricular assist device specialist healthcare provider: Part 2: at the emergency department. ESC Heart Failure, 2021, 8, 4409-4424.	1.4	7
671	Chemoreceptor-Baroreceptor Interactions in Cardiovascular Disease. Lung Biology in Health and Disease, 2000, , 33-60.	0.1	7
672	Validation of transurethral intra‑abdominal pressure measurement in acute heart failure. Polish Archives of Internal Medicine, 2018, 128, 403-405.	0.3	7
673	Cardiac emergencies during the coronavirus disease 2019 pandemic in the light of the current evidence. Kardiologia Polska, 2020, 78, 818-824.	0.3	7
674	Testosterone deficiency in men with heart failure: pathophysiology and its clinical, prognostic and therapeutic implications. Kardiologia Polska, 2014, 72, 403-409.	0.3	7
675	Human carotid bodies as a therapeutic target: new insights from a clinician's perspective. Kardiologia Polska, 2018, 76, 1426-1433.	0.3	7
676	Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute HeartÂFailure. JACC: Heart Failure, 2021, 9, 890-903.	1.9	7
677	Acute hyperoxia reveals tonic influence of peripheral chemoreceptors on systemic vascular resistance in heart failure patients. Scientific Reports, 2021, 11, 20823.	1.6	7
678	True worsening renal function identifies patients with acute heart failure with an ominous outcome. Polish Archives of Internal Medicine, 2019, 129, 357-360.	0.3	7
679	Repetitive use of LEvosimendan in Ambulatory Heart Failure patients (LEIA-HF) - The rationale and study design. Advances in Medical Sciences, 2022, 67, 18-22.	0.9	7
680	Determinants of physical fitness in males with systolic heart failure. Kardiologia Polska, 2010, 68, 146-54.	0.3	7
681	Clinical implications of low estimated protein intake in patients with heart failure. Journal of Cachexia, Sarcopenia and Muscle, 2022, , .	2.9	7
682	Treatment of Anemia With Darbepoetin Alfa in Heart Failure. Congestive Heart Failure, 2010, 16, 87-95.	2.0	6
683	Serum phosphorus level is related to degree of clinical response to up-titration of heart failure pharmacotherapy. International Journal of Cardiology, 2014, 177, 248-254.	0.8	6
684	Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure — Post-hoc analysis of the PROTECT trial. International Journal of Cardiology, 2016, 223, 967-975.	0.8	6

#	Article	IF	CITATIONS
685	What's new in the European Society of Cardiology 2016 Guidelines for the diagnosis and treatment of acute and chronic heart failure?. European Heart Journal, 2016, 37, 3121-3122.	1.0	6
686	Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. Clinical Proteomics, 2018, 15, 35.	1.1	6
687	Intravenous iron supplementation: novel anti-remodelling therapy for patients with heart failure?. European Heart Journal, 2021, , .	1.0	6
688	The Role of Pharmacological Treatment in the Chemoreflex Modulation. Frontiers in Physiology, 0, 13,	1.3	6
689	Lateâ€onset hypogonadism in men with systolic heart failure: prevalence, clinical associates, and impact on longâ€ŧerm survival. ESC Heart Failure, 2014, 1, 41-51.	1.4	5
690	Psychological Gender of Men With Systolic Heart Failure. American Journal of Men's Health, 2014, 8, 249-257.	0.7	5
691	lohexol clearance is superior to creatinine-based renal function estimating equations in detecting short-term renal function decline in chronic heart failure. Croatian Medical Journal, 2015, 56, 531-541.	0.2	5
692	Psychological aspects of heart failure – beyond depression, anxiety and quality of life. Health Psychology Report, 2015, 3, 99-114.	0.5	5
693	CUPID 2: A Phase 2b Trial Investigating the Efficacy and Safety of the Intracoronary Administration of AAV1/SERCA2a in Patients with Advanced Heart Failure. Journal of Cardiac Failure, 2015, 21, 939-940.	0.7	5
694	Resting Heart Rate and Ischemic Stroke in Patients with Heart Failure. Cerebrovascular Diseases, 2017, 44, 43-50.	0.8	5
695	Drug therapy in elderly heart failure patients. European Heart Journal Supplements, 2019, 21, L8-L11.	0.0	5
696	10Âyear trends in hospitalization rates due to heart failure and related inâ€hospital mortality in Poland (2010–2019). ESC Heart Failure, 2020, 7, 3365-3373.	1.4	5
697	Looking at the heart failure through the prism of liver dysfunction. European Journal of Heart Failure, 2020, 22, 1672-1674.	2.9	5
698	Not all fluid overloads are the same: some practical considerations for better decongestion. European Journal of Heart Failure, 2021, 23, 1106-1109.	2.9	5
699	Targeting Iron Deficiency in Heart Failure: Existing Evidence and Future Expectations. Circulation: Heart Failure, 2021, 14, e008299.	1.6	5
700	Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials. Circulation, 2021, 144, 1265-1267.	1.6	5
701	HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the nonâ€hospital settings in the community. ESC Heart Failure, 2021, 8, 4394-4408.	1.4	5
702	Heart failure: preventing disease and death worldwide. ESC Heart Failure, 2014, 1, n/a-n/a.	1.4	5

#	Article	IF	CITATIONS
703	Comprehensive Heart Failure Care pilot study: starting point and expected developments. Kardiologia Polska, 2019, 77, 994-999.	0.3	5
704	Differences in the Biomarker Profile of De Novo Acute Heart Failure versus Decompensation of Chronic Heart Failure. Biomolecules, 2021, 11, 1701.	1.8	5
705	Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk inÂDAPA-HF. JACC: Heart Failure, 2022, 10, 104-118.	1.9	5
706	The role of exercise ventilation in clinical evaluation and risk stratification in patients with chronic heart failure. Kardiologia Polska, 2003, 59, 115-27; commentary 126-7.	0.3	5
707	Corrigendum to â€~ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008' [Eur Heart J 2008;29:2388-2442 and Eur J Heart Fail 2008;10:933-989]. European Journal of Heart Failure, 2009, 11, 110-110.	2.9	4
708	Sex Hormone-Binding Globulin and Heart Failure: a Passive Carrier of Steroid Hormones or an Active Hormone Itself?. Revista Espanola De Cardiologia (English Ed ), 2009, 62, 1353-1355.	0.4	4
709	Heart Failure Classifications – Guidelines. Contributions To Nephrology, 2010, 164, 11-23.	1.1	4
710	Guidelines for the management of atrial fibrillation. Europace, 2011, 13, 1058-1058.	0.7	4
711	'Iron deficiency: an ominous sign in patients with systolic chronic heart failure' [Eur Heart J 2010;31:1872-1880, doi:10.1093/eurheartj/ehq158]. European Heart Journal, 2011, 32, 1054-1054.	1.0	4
712	The effect of diabetes on the diagnostic and prognostic performance of mid-region pro-atrial natriuretic peptide and mid-region pro-adrenomedullin in patients with acute dyspnea. Biomarkers, 2012, 17, 490-497.	0.9	4
713	Association of quality of life with anticoagulant control in patients with heart failure: The Warfarin and Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial. International Journal of Cardiology, 2014, 177, 715-717.	0.8	4
714	Sex differences in porcine left ventricular myocardial remodeling due to right ventricular pacing. Biology of Sex Differences, 2015, 6, 32.	1.8	4
715	Current and emerging pharmacologic options for the management of patients with chronic and acute decompensated heart failure. Expert Review of Clinical Pharmacology, 2017, 10, 517-534.	1.3	4
716	Proportional pulse pressure relates to cardiac index in stabilized acute heart failure patients. Clinical and Experimental Hypertension, 2018, 40, 637-643.	0.5	4
717	Expert opinion of the Heart Failure Working Group of the Polish Cardiac Society on the use of dapagliflozin in the treatment of heart failure with reduced ejection fraction. Kardiologia Polska, 2021, 79, 363-370.	0.3	4
718	Iron status, catabolic/anabolic balance, and skeletal muscle performance in men with heart failure with reduced ejection fraction. Cardiology Journal, 2021, 28, 391-401.	0.5	4
719	Role of skeletal muscle perfusion and insulin resistance in the effect of dietary sodium on heart function in overweight. ESC Heart Failure, 2021, 8, 5304-5315.	1.4	4
720	Nordic Walking May Safely Increase the Intensity of Exercise Training in Healthy Subjects and in Patients with Chronic Heart Failure. Advances in Clinical and Experimental Medicine, 2016, 25, 145-149.	0.6	4

#	Article	IF	CITATIONS
721	Cardioversion differences among first detected episode, paroxysmal, and persistent atrial fibrillation patients in the RHYTHM AF registry in Poland. Cardiology Journal, 2015, 22, 453-458.	0.5	4
722	Acute heart failure in patients admitted to the emergency department with acute myocardial infarction. Kardiologia Polska, 2017, 75, 306-315.	0.3	4
723	Impact of digoxin on risk of death in heart failure patients treated with b-blockers. Results from Polish part of ESC Heart Failure Long-Term Registry. Kardiologia Polska, 2018, 76, 1064-1072.	0.3	4
724	Andropausal syndrome in men with systolic heart failure. Polish Archives of Internal Medicine, 2013, 123, 156-169.	0.3	4
725	Hemosiderin Accumulation in Liver Decreases Iron Availability in Tachycardia-Induced Porcine Congestive Heart Failure Model. International Journal of Molecular Sciences, 2022, 23, 1026.	1.8	4
726	Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 228-239.	2.2	4
727	Persistent high NTpro-BNP concentration as a negative prognostic factor in patients with decompensated heart failure. Kardiologia Polska, 2006, 64, 250-6; discussion 257-8.	0.3	4
728	Effect of carvedilol on exercise tolerance in patients with chronic heart failure and a restrictive left ventricular filling pattern. American Journal of Cardiology, 2003, 91, 1281-1283.	0.7	3
729	Changes in Dyspnea during Treatment of Acute Heart Failure Are Correlated with Clinical Signs, Rehospitalizations and Mortality. Results from the Pre-RELAX-AHF Trial. Journal of Cardiac Failure, 2009, 15, S62-S63.	0.7	3
730	Relations between professional medical associations and healthcare industry, concerning scientific communication and continuing medical education: a Policy Statement from the European Society of Cardiology. Revista Portuguesa De Cardiologia, 2012, 31, 529-538.	0.2	3
731	Renal failure in patients with heart failure - analysis based on ESC-HF Pilot survey. European Heart Journal, 2013, 34, P645-P645.	1.0	3
732	Hypoglycaemia in diabetic patients: highly undesirable by cardiologists. European Heart Journal, 2013, 34, 3102-3105.	1.0	3
733	Anaemia (and iron deficiency?) in aortic stenosis—a bystander or a potential therapeutic target?. European Journal of Heart Failure, 2015, 17, 994-996.	2.9	3
734	Central Chemoreceptor Sensitivity Is Not Enhanced in Contemporary Patients With Chronic Systolic Heart Failure Receiving Optimal Treatment. Journal of Cardiac Failure, 2017, 23, 83-87.	0.7	3
735	The story of carotid body resection for HF. European Heart Journal, 2017, 38, 3481-3482.	1.0	3
736	Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial). American Journal of Cardiology, 2018, 122, 821-827.	0.7	3
737	Catabolic/Anabolic Imbalance Is Accompanied by Changes of Left Ventricular Steroid Nuclear Receptor Expression in Tachycardia-Induced Systolic Heart Failure in Male Pigs. Journal of Cardiac Failure, 2021, 27, 682-692.	0.7	3
738	Intravenous ferric carboxymaltose does not provide benefits in reperfused acute myocardial infarction in the rat with normal iron status. Biomedicine and Pharmacotherapy, 2021, 141, 111893.	2.5	3

#	Article	IF	CITATIONS
739	Abnormal serum calcium levels are associated with clinical response to maximization of heart failure therapy. Polish Archives of Internal Medicine, 2015, 125, 54-64.	0.3	3
740	Iron deficiency in heart failure: a 2020 update. Kardiologia Polska, 2019, 77, 1134-1139.	0.3	3
741	Sexual dimorphism in socioeconomic differences regarding the risk factors, symptomatology and management of patients with stable coronary artery disease in Poland. Cardiology Journal, 2015, 22, 487-494.	0.5	3
742	Demographic and clinical characteristics of patients with atrial fibrillation and cardioversion as planned therapeutic options in the International Registry on Cardioversion of Atrial Fibrillation RHYTHM-AF Polish substudy. Kardiologia Polska, 2014, 72, 700-706.	0.3	3
743	Recommendations on the use of innovative medical technologies in cardiology and cardiac surgery and solutions leading to increased availability for Polish patients. Cardiology Journal, 2019, 26, 114-129.	0.5	3
744	Medical emergency team interventions in patients with ST-segment elevation myocardial infarction in Poland in 2018. Kardiologia Polska, 2020, 78, 292-299.	0.3	3
745	679 Reduction in serum testosterone deteriorates exercise capacity in men in the course of chronic heart failure. European Journal of Heart Failure, Supplement, 2007, 6, 148-148.	0.2	2
746	Treatment of advanced chronic heart failure with normal left ventricular ejection fraction. Response to the letter by Dr. Martinez‧elles. European Journal of Heart Failure, 2007, 9, 1224-1225.	2.9	2
747	Vasodilators in Acute Heart Failure (AHF): Does Blood Pressure Matter? Results from Pre-Relax-AHF. Journal of Cardiac Failure, 2009, 15, S74.	0.7	2
748	Corrigendum to â€~Adherence of heart failure patients to exercise: barriers and possible solutions. A position statement of the Study Group on Exercise Training in Heart Failure of the Heart Failure Association of the European Society of Cardiology' [Eur J Heart Fail 2012;14:451–458]. European Journal of Heart Failure, 2012, 14, 802-802.	2.9	2
749	Relations between professional medical associations and healthcare industry, concerning scientific communication and continuing medical education: a Policy Statement from the European Society of Cardiology. Revista Portuguesa De Cardiologia (English Edition), 2012, 31, 529-538.	0.2	2
750	Elevated serum lactate is a marker of organ damage related to impaired hemodynamics and indicates poor prognosis in acute heart failure. European Heart Journal, 2013, 34, P1517-P1517.	1.0	2
751	HIGH SOLUBLE TRANSFERRIN RECEPTOR IN PATIENTS WITH SYSTOLIC HEART FAILURE: A MEASURE OF IRON DEFICIENCY AND A STRONG PREDICTOR OF MORTALITY. Journal of the American College of Cardiology, 2013, 61, E749.	1.2	2
752	Changes in parasympathetic system in medulla oblongata in male pigs in the course of tachycardia-induced cardiomyopathy. Autonomic Neuroscience: Basic and Clinical, 2013, 177, 253-259.	1.4	2
753	Aspirin Does Not Increase Heart FailureÂEvents in Heart Failure Patients. JACC: Heart Failure, 2017, 5, 603-610.	1.9	2
754	Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. International Journal of Cardiology, 2018, 253, 91-96.	0.8	2
755	Seat beltsâ€related behaviors in car drivers with cardiac implantable electronic devices. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 400-406.	0.5	2
756	Frailty and cognitive impairment are predictive of takotsubo syndrome following pacemaker implantation. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 730-736.	0.5	2

#	Article	IF	CITATIONS
757	Antiplatelets in acute coronary syndrome in Poland – from guidelines to clinical practice. Postepy W Kardiologii Interwencyjnej, 2021, 17, 141-154.	0.1	2
758	InterAtrial Shunt Device (IASD®) implantation — a novel treatment method for heart failure with preserved ejection fraction. Kardiologia Polska, 2017, 75, 736-741.	0.3	2
759	Relationship between the CHA2DS2-VASc score and atrial fibrillation in patients hospitalised due to heart failure. Kardiologia Polska, 2019, 77, 380-385.	0.3	2
760	Phrenic nerve stimulation in patients with central sleep apnea: a single‑center experience from pilot and pivotal trials evaluating the remedē System. Kardiologia Polska, 2019, 77, 553-560.	0.3	2
761	Cardioversion of Atrial Fibrillation (RHYTHM-AF) International Registry in Poland. Cardiology Journal, 2014, 21, 484-491.	0.5	2
762	Clinical profile and management of outpatients with non-ischemic and non-hypertensive systolic heart failure: Analysis of the Polish DATA-HELP registry. Cardiology Journal, 2018, 25, 512-520.	0.5	2
763	Prognostic importance of serum troponin concentration in patients with an implanted cardioverter‑defibrillator admitted to the emergency department due to electric shock. Kardiologia Polska, 2019, 77, 618-623.	0.3	2
764	Abnormal indices of autonomic function are no longer predictors of poor outcome in diabetic patients without neuropathy but with coexisting coronary artery disease who receive optimal pharmacological therapy. Kardiologia Polska, 2009, 67, 1325-32.	0.3	2
765	Early Hemodynamic Changes following Surgical Ablation of the Right Greater Splanchnic Nerve for the Treatment of Heart Failure with Preserved Ejection Fraction. Journal of Clinical Medicine, 2022, 11, 1063.	1.0	2
766	Effects of Dapagliflozin in Asian Patients With HeartÂFailure and Reduced Ejection Fraction in DAPA-HF. JACC Asia, 2022, , .	0.5	2
767	Contribution of Peripheral Chemoreceptors to Exercise Intolerance in Heart Failure. Frontiers in Physiology, 2022, 13, 878363.	1.3	2
768	Novel Biomarkers of Renal Dysfunction and Congestion in Heart Failure. Journal of Personalized Medicine, 2022, 12, 898.	1.1	2
769	Usefulness of the P Wave Signal-Averaged Electrocardiogram in Predicting Patients at Risk of Atrial Flutter and Fibrillation Induced by Transesophageal Pacing. Annals of Noninvasive Electrocardiology, 1999, 4, 46-52.	0.5	1
770	PRESTO (a mammoth trial that could have been prevented), HPS and REMATCH. International Journal of Cardiology, 2002, 83, 99-102.	0.8	1
771	Beta-Blocker Treatment Before Angiotensin-Converting Enzyme Inhibitor Therapy in Newly Diagnosed Heart Failure. Journal of the American College of Cardiology, 2005, 46, 182.	1.2	1
772	Intravenous Iron Sucrose in Anemic and Non-anemic Iron Deficient Patients with CHF: A Randomized, Controlled, Observer-blinded Intervention Study (FERRIC-HF). Journal of Cardiac Failure, 2006, 12, S179.	0.7	1
773	Response to Letter Regarding Article, "Anabolic Deficiency in Men With Chronic Heart Failure: Prevalence and Detrimental Impact on Survivalâ€: Circulation, 2007, 115, .	1.6	1
774	Time to Treatment and Vasodilator Efficacy in Acute Heart Failure: Results from the Pre-RELAX-AHF Study. Journal of Cardiac Failure, 2009, 15, S68.	0.7	1

#	ARTICLE	IF	CITATIONS
775	Corrigendum to: Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: The Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA)' [Eur Heart J 2009;30:2769-2812].	1.0	1
776	Anticoagulación para pacientes con insuficiencia cardiaca en ritmo sinusal: habitual en la práctica clÃnica, pero aún no basada en la evidencia. Revista Espanola De Cardiologia, 2012, 65, 687-689.	0.6	1
777	Consequences of Peripheral Chemoreflex Inhibition with Low-Dose Dopamine in Humans. Journal of Physiology, 2014, , n/a-n/a.	1.3	1
778	Central Sleep Apnea in Heart Failure Worsens Throughout the Night. Chest, 2015, 148, 1047A.	0.4	1
779	Non-invasive approach for the assessment of sympathetic baroreflex function: A feasibility study. Autonomic Neuroscience: Basic and Clinical, 2017, 203, 108-112.	1.4	1
780	Phrenic Nerve Simulation for Central Sleep Apnea is Effective and Safe in the Presence of Concomitant Cardiac Devices. Journal of Cardiac Failure, 2018, 24, S17-S18.	0.7	1
781	Pulse pressure and prognosis in patients with heart failure with reduced ejection fraction. European Journal of Clinical Investigation, 2019, 49, e13092.	1.7	1
782	Myocardial iron content in nonâ€ischaemic cardiomyopathy: how much is known?. European Journal of Heart Failure, 2020, 22, 2047-2048.	2.9	1
783	FC 021EFFICACY OF INTRAVENOUS FERRIC CARBOXYMALTOSE IN PATIENTS WITH IRON DEFICIENCY FOLLOWING ACUTE HEART FAILURE, ACCORDING TO BASELINE EGFR: A SUBGROUP ANALYSIS OF THE AFFIRM-AHF TRIAL. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	1
784	Low ventilatory responsiveness to transient hypoxia or breath-holding predicts fast marathon performance in healthy middle-aged and older men. Scientific Reports, 2021, 11, 10255.	1.6	1
785	Pol-tako — the first, nationwide Polish multicenter analysis of patients with takotsubo syndrome. Kardiologia Polska, 2021, 79, 867-869.	0.3	1
786	Combined testosterone and insulin-like growth factor deficiency impairs quadriceps strength in men with chronic heart failure. European Journal of Heart Failure, Supplement, 2008, 7, 2-3.	0.2	1
787	1453 In majority of patients with intermediate coronary lesions increased doses of intracoronary adenosine are required for the reliable assessment of fractional flow reserve. European Heart Journal, 2003, 24, 264.	1.0	1
788	Valsalva-derived Measures and Phenylephrine Test in Patients With Heart Failure With Reduced Ejection Fraction Receiving Comprehensive Neurohormonal Blockade Drug Therapy: A 5-year Event-free Survival Analysis. Journal of Cardiac Failure, 2022, 28, 744-755.	0.7	1
789	OUP accepted manuscript. European Heart Journal, 2021, , .	1.0	1
790	Iron deficiency as an emerging therapeutic target in patients stabilized after an episode of acute heart failure. Cardiology Journal, 2021, 28, 962-969.	0.5	1
791	Editorial comment on effect of exercise training in patients with heart failure. European Journal of Cardiovascular Prevention and Rehabilitation, 2004, 11, 168-170.	3.1	0
792	Rationale and design of CIBIS III. Country Review Ukraine, 2006, 8, C35-C42.	0.8	0

#	Article	IF	CITATIONS
793	Hematinics in Patients with Complicated Acute Myocardial Infarction: Results from an OPTIMAAL Substudy. Journal of Cardiac Failure, 2008, 14, S34.	0.7	0
794	Prognostic Value of Mid-Regional Pro-Adrenomedullin in Patients with Chronic Heart Failure (CHF). Journal of Cardiac Failure, 2008, 14, S90.	0.7	0
795	Worsening Renal Function in Acute Heart Failure: Change in Blood Pressure and Effects of Relaxin. Journal of Cardiac Failure, 2009, 15, S63.	0.7	0
796	Troponin Release in Patients Admitted with Acute Decompensated Heart Failure and Renal Dysfunction: Results from the Pilot Phase of the PROTECT Trial. Journal of Cardiac Failure, 2009, 15, S36-S37.	0.7	0
797	GuÃa de práctica clÃnica para la valoración del riesgo cardiaco preoperatorio y el manejo cardiaco perioperatorio en la cirugÃa no cardiaca. Revista Espanola De Cardiologia (English Ed ), 2009, 62, 1467.e1-1467.e56.	0.4	0
798	Treating in-stent restenosis with drug-eluting balloon with intracoronary ultrasound control, with later optical coherent tomography control. Postepy W Kardiologii Interwencyjnej, 2010, 4, 203-207.	0.1	0
799	The PROTECT In-Hospital Risk Model: 7-Day Outcome in Patients Hospitalized with Acute Heart Failure (AHF) and Renal Dysfunction. Journal of Cardiac Failure, 2011, 17, S77.	0.7	0
800	International Differences in Acute Heart Failure (AHF) Patients: Insight from the PROTECT Trial. Journal of Cardiac Failure, 2011, 17, S59-S60.	0.7	0
801	Single Night Transvenous Phrenic Nerve Stimulation Improves Central Sleep Apnoea In Systolic Heart Failure. , 2011, , .		0
802	Anticoagulation for Heart Failure Patients in Sinus Rhythm: Common in Clinical Practice But Still Not Evidence-based. Revista Espanola De Cardiologia (English Ed ), 2012, 65, 687-689.	0.4	0
803	Phrenic Nerve Stimulation Improves Circulatory Delay in Patients With Heart Failure and Central Sleep Apnea. Journal of Cardiac Failure, 2012, 18, S14-S15.	0.7	0
804	Age, Clinical Characteristics and Outcomes of Patients With Acute Decompensated Heart Failure: Insights from the PROTECT Trial. Journal of Cardiac Failure, 2012, 18, S76.	0.7	0
805	CoreValve transcatheter aortic valve implantation complicated by stress cardiomyopathy (tako-tsubo) and septic shock. Postepy W Kardiologii Interwencyjnej, 2012, 4, 335-337.	0.1	0
806	URSODEOXYCHOLIC ACID IN PATIENTS WITH CHRONIC HEART FAILURE. A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, CROSSOVER TRIAL. Rational Pharmacotherapy in Cardiology, 2012, 8, 110-117.	0.3	0
807	Coronary rotational atherectomy in patients with unsuccessful classical angioplasty – in-hospital and six-month follow-up. Postepy W Kardiologii Interwencyjnej, 2012, 2, 85-90.	0.1	0
808	Hypercapnic Chemosensitivity in Patients with Heart Failure: Relation to Shifts in Type-1 Insulin-Like Growth Factor and Sex Hormone-Binding Globulin Levels. Neurophysiology, 2013, 45, 133-139.	0.2	0
809	Management of Chronic Heart Failure – Update 2013. Journal of Cardiac Failure, 2013, 19, S109.	0.7	0
810	Gender-related differences in the clinical characteristics, pharmacotherapy and outcomes in the one-year follow-up in the Polish population of heart failure pilot survey. European Heart Journal, 2013, 34, P3340-P3340.	1.0	0

#	Article	lF	CITATIONS
811	Low-dose dopamine infusion increases baroreflex sensitivity by inhibition of peripheral chemoreflex. European Heart Journal, 2013, 34, P2366-P2366.	1.0	0
812	Heart Failure with Preserved left ventricular Ejection Fraction (HFPEF) in the Polish population of the ESC EURObservational research programme: the heart failure pilot registry. European Heart Journal, 2013, 34, P2474-P2474.	1.0	0
813	Symptoms associated with male aging in men with systolic heart failure. European Heart Journal, 2013, 34, P5733-P5733.	1.0	0
814	Dopamine withdrawal causes chemoreflex-related increase in minute ventilation. European Heart Journal, 2013, 34, P576-P576.	1.0	0
815	Percutaneous reduction of mitral valve regurgitation using the MitraClip system – immediate and 90-day follow-up of 3 cases. Postepy W Kardiologii Interwencyjnej, 2013, 2, 126-131.	0.1	0
816	Design and Rationale of the Soluble Guanylate Cyclase Stimulator in Heart Failure Studies (SOCRATES). Journal of Cardiac Failure, 2014, 20, S39.	0.7	0
817	Considerable Regional Variation in AAV1 Neutralizing Antibodies and Its Consequences for a Multinational Clinical Trial of Gene Transfer for Advanced Heart Failure: The CUPID 2 Experience. Journal of Cardiac Failure, 2014, 20, S93.	0.7	0
818	Prevalence of Central Sleep Apnea in Patients Screened During the remedē® System Pilot Study. Journal of Cardiac Failure, 2014, 20, S117-S118.	0.7	0
819	Effect of short-term rapid ventricular pacing followed by pacing interruption on arterial blood pressure in healthy pigs and pigs with tachycardiomyopathy. Polish Journal of Veterinary Sciences, 2014, 17, 85-91.	0.2	0
820	Prediction of Post-Discharge Outcomes for Patients Hospitalized with Heart Failure: Results from PROTECT. Journal of Cardiac Failure, 2015, 21, S64.	0.7	0
821	Late Cardiac Tamponade as a Result of Parietal Pericardium Erosion. Annals of Thoracic Surgery, 2015, 100, 715-717.	0.7	0
822	Iron Deficiency in Heart Failure. , 2016, , 535-547.		0
823	Contemporary Pharmacological Treatment of Heart Failure. , 2016, , 207-227.		0
824	In Heart Failure Patients with CSA, Stimulation of the Phrenic Nerve Improves Sleep and Quality of Life. Journal of Cardiac Failure, 2017, 23, S15.	0.7	0
825	Transvenous Phrenic Nerve Stimulation Effectiveness is Sustained at 18 Months: Data From the Remede System Pivotal Trial. Chest, 2017, 152, A734.	0.4	0
826	Muscle Ergoreflex Activity and Autonomic Balance Assessed in the Vertical and Horizontal Body Positions in Young Healthy Men. Neurophysiology, 2017, 49, 288-294.	0.2	0
827	253Effect of i.v. ferric carboxymaltose iron therapy on symptoms and functional status in iron-deficient patients with HFrEF and renal dysfunction: An individual patient data meta-analysis. European Heart Journal, 2017, 38, .	1.0	0
828	Expression of α7 Nicotinic ACh Receptors in Blood Mononuclear Cells: Correlation with Impaired Baroreflex Sensitivity in Patients with Heart Failure. Neurophysiology, 2018, 50, 249-253.	0.2	0

#	Article	IF	CITATIONS
829	Effect of Implantable Cardioverter-Defibrillators by Etiology of Heart Failure: A Propensity-Matched Mortality Analysis of the WARCEF Trial. Journal of Cardiac Failure, 2018, 24, S75.	0.7	0
830	The Relationship between LVEF and Cardiovascular Outcomes Following Hospitalization for Heart failure: Insights from the RELAX-AHF-2 Trial. Journal of Cardiac Failure, 2019, 25, S55.	0.7	0
831	Association between Left Ventricular Ejection Fraction and Worsening Renal Function in Acute Heart Failure: Insights from the RELAX-AHF-2 Trial. Journal of Cardiac Failure, 2019, 25, S51.	0.7	Ο
832	Re: Pacing, takotsubo syndrome, and transient rise of pacing threshold: What is the mechanism?. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 772-773.	0.5	0
833	The short-term benefit from nurse-led ambulatory care supported by non-invasive haemodynamic assessment in patients after acute heart failure decompensation depends on time since hospital discharge. Kardiologia Polska, 2021, 79, 855-857.	0.3	0
834	1350 Ergoreflex contribution to ventilatory response assessed during exercise of forearm and quadriceps muscles in patients with chronic heart failure. European Heart Journal, 2003, 24, 259.	1.0	0
835	P1581 Ventilatory response to early phase of exercise: a novel index useful for the comprehensive assessment of patients with chronic heart failure. European Heart Journal, 2003, 24, 288.	1.0	Ο
836	1347 Excessive ventilation during early phase of exercise predicts poor outcome in patients with chronic heart failure. European Heart Journal, 2003, 24, 258.	1.0	0
837	3635 Statin therapy and survival in 2068 chronic heart failure patients: ischaemic versus non-ischaemic etiology. European Heart Journal, 2003, 24, 708.	1.0	Ο
838	2594 The activation of the nuclear factor-?B system in chronic heart failure. European Heart Journal, 2003, 24, 488.	1.0	0
839	P3243 Endotoxin inhibits apoptosis in ex vivo mononuclear blood cells from patients with chronic heart failure. European Heart Journal, 2003, 24, 611.	1.0	Ο
840	853 In chronic heart failure overactive chemokine system is associated with immune activation, low grade inflammation and predicts loss of fat tissue. European Heart Journal, 2003, 24, 145.	1.0	0
841	1929 Insulin resistance predicts impaired survival in chronic heart failure. European Heart Journal, 2003, 24, 362.	1.0	Ο
842	677 Does andropause exist in men with chronic heart failure, and is it linked to multiple anabolic deficiency ?. European Journal of Heart Failure, Supplement, 2007, 6, 147-148.	0.2	0
843	542 Pentoxifylline improves the haemoglobin levels in anaemic patients with chronic heart failure. European Journal of Heart Failure, Supplement, 2007, 6, 124-124.	0.2	0
844	343 Depression in men with chronic heart failure: prevalence and hormone determinants. European Journal of Heart Failure, Supplement, 2007, 6, 78-78.	0.2	0
845	245 Prognostic utility of growth-differentiation factor-15 in patients with chronic heart failure. European Journal of Heart Failure, Supplement, 2007, 6, 46-47.	0.2	0
846	857 Serum hepcidin is not linked to iron status in patients with chronic heart failure. European Journal of Heart Failure, Supplement, 2007, 6, 186-186.	0.2	0

#	Article	IF	CITATIONS
847	75 Oscillatory ventilation at rest coexisting with increased ventilatory response to exercise allow to identify heart failure patients with very poor outcome. European Journal of Heart Failure, Supplement, 2007, 6, 15-15.	0.2	0
848	Sexual complaints in men with chronic heart failure: prevalence and hormone determinants. European Journal of Heart Failure, Supplement, 2008, 7, 118-118.	0.2	0
849	Reduced Circulating Levels of Testosterone and Insulin-Like Growth Factor Predict the Prevalence of Hyperuricaemia, the Major Cardiovascular Risk Factor, in Men with Systolic Chronic Heart Failure , 2010, , P1-402-P1-402.		0
850	Iron deficiency in patients with chronic kidney disease requiring hemodialysis: do inflammation and overexpressed hepcidin contribute significantly?. Polish Archives of Internal Medicine, 2013, 123, 68-70.	0.3	0
851	P-R interval in porcine model of chronic tachycardia-induced cardiomyopathy. Bulletin of the Veterinary Institute in Pulawy = Biuletyn Instytutu Weterynarii W Pulawach, 2013, 57, 437-441.	0.4	0
852	Does right ventricular pacing increase the risk of ventricular arrhythmias in patients with an implantable cardioverter-defibrillator?. Kardiologia Polska, 2014, 72, 381-384.	0.3	0
853	Increase in heart failure mortality in Poland: can we explain the reasons?. Polish Archives of Internal Medicine, 2014, 124, 274-275.	0.3	0
854	Attitude towards knowledge of the disease and psychological characteristics of patients with systolic heart failure. Health Psychology Report, 2017, 1, 30-40.	0.5	0
855	Sacubitril/valsartan for treatment of chronic heart failure with reduced ejection fraction. Can all patients benefit? A position statement paper of experts of the Heart Failure Working Group of the Polish Cardiac Society. Kardiologia Polska, 2017, 75, 286-293.	0.3	0
856	Sacubitril/valsartan for treatment of chronic heart failure with reduced ejection fraction. Can all patients benefit? A position statement paper of experts of the Heart Failure Working Group of the Polish Cardiac Society. Kardiologia Polska, 2017, 75, 33-41.	0.3	0
857	Chloroquine and hydroxychloroquine for the prevention and therapy of coronavirus disease 2019: new hopes and old cardiovascular concerns. Kardiologia Polska, 2020, 78, 811-817.	0.3	0
858	Predictors of inappropriate shocks from implantable cardioverter-defibrillators. Wiadomości Lekarskie, 2019, 72, 1243-1246.	0.1	0
859	128 Clinical impact of changes in mitral regurgitation severity after optimization of medical therapy in heart failure: insights from BIOSTAT-CHF. European Heart Journal Supplements, 2021, 23, .	0.0	0
860	Induction of Day-Time Periodic Breathing is Associated With Augmented Reflex Response From Peripheral Chemoreceptors in Male Patients With Systolic Heart Failure. Frontiers in Physiology, 2022, 13, .	1.3	0